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ABSTRACT
The neurodegenerative disorder Parkinson’s disease is often diagnosed when
motor symptoms appear, at which time approximately 30% of the substantia
nigra dopamine neurons have already died. The majority of disease cases are
idiopathic, and there are currently no disease-modifying therapies. Since the
specific molecular mechanisms underlying Parkinson’s disease are still
unknown, bringing treatments to the clinic has been difficult. However, in
searching for both the underlying aetiology of the disease and a cure for it,
animal models have brought valuable insights. Parkinson’s disease animal
models have been developed using toxins to cause nigrostriatal degeneration,
genetic manipulation, and through the use of alpha-synuclein. Alpha-
synuclein is a 14 kDa protein found abundantly in the central nervous system
of vertebrates. Its importance for Parkinson’s disease was clarified when it
was discovered that mutations in the gene led to an autosomal dominant
disease form and that it is the majority protein in what is considered a
pathological marker of the disease, Lewy bodies. With these discoveries,
alpha-synuclein animal models became an important tool in Parkinson’s
disease research.
Cerebral dopamine neurotrophic factor (CDNF) is a highly conserved protein
in vertebrates with neurotrophic-like properties. It has been shown to protect
dopamine neurons in rodent toxin models of Parkinson’s disease and is
currently in Phase I/II clinical trials for the disease. It has not been tested in
alpha-synuclein animal models however, and therefore the aim of these
studies was to model alpha-synuclein-based Parkinson’s disease in rodents
and to test whether CDNF can intervene with alpha-synuclein aggregation
and has therapeutic effects in these models.
We generated two models that used alpha-synuclein specifically to attempt to
model sporadic Parkinson’s disease in rodents and test CDNF on: adeno-
associated virus (AAV) and preformed fibrils. We used an AAV to overexpress
human wild-type alpha-synuclein in rats by injecting the virus above the
substantia nigra, with the end goal to test CDNF. We successfully modeled the
nigrostriatal dopamine loss observed accompanied by some behavioural
deficits, however, the variation in the success of the model was too high to
consider it feasible to test CDNF on. This, combined with concerns about
controls, led us to conclude that it may not be an ideal model of sporadic
Parkinson’s disease to test therapies on. Next, we used a preformed alpha-
synuclein fibrils model in both mice and rats to seed endogenous alpha-
synuclein after striatal injection with the goal to induce nigrostriatal
dopamine neuron degeneration, progressive Lewy-like pathology spreading,
and observe motor behavioural deficiencies in order to test CDNF. Here, we
observed modest behavioural deficits that were ameliorated by CDNF,
however the model did not result in dopamine neuron loss with the measures
used. Importantly, we were able to model the spreading of Lewy body- and
Lewy neurite-like inclusions that were positive for phosphorylated alpha-
synuclein. After injection to the striatum there was progressive spreading of
phosphorylated alpha-synuclein to the cortex and substantia nigra, which has
vbeen shown in previous studies. While we had mildly positive effects with
CDNF and from parallel in vitro studies we can conclude that the protein is
affecting the preformed alpha-synuclein fibrils model, further studies are
needed to clarify this.
We also wanted to further study CDNF, and for this we used the classic 6-
hydroxydopamine (6-OHDA) toxin to selectively destroy the dopamine
neurons of the nigrostriatal tract in order to model Parkinson’s disease. Since
CDNF has been successful in the 6-OHDA model after striatal injection, we
tested injection to the substantia nigra, and also characterized the injection in
naïve rats. We expected similar effects of CDNF on dopamine neurons and
behaviour using nigral injection, however issues with the injection paradigm
for 6-OHDA and that CDNF was given only as a single injection, resulted in
only minor behavioural effects and no restoration of dopamine neurons.
Although we demonstrated that when CDNF is injected to the substantia
nigra of naïve rats, it is not transported to the striatum, but rather diffused
around the midbrain and is taken up by nigral tyrosine hydroxylase positive
neurons.
In addition to the above specific alpha-synuclein models, we used a
proteasomal inhibitor, the lactacystin toxin, to characterize another model of
Parkinson’s disease. When lactacystin was injected above the substantia nigra
of mice, we observed a buildup of alpha-synuclein, some nigrostriatal
dopamine loss, neuroinflammation, and mild behavioural deficits. In general,
this was repeated successfully and could be a model used for therapeutic
studies.
In conclusion, we had success in modeling the progressive spreading of Lewy
body-like pathology and alpha-synuclein aggregation, a phenomenon that is
occurring in Parkinson’s disease. However, we were not able to test CDNF in
the model of AAV-alpha-synuclein overexpression due to high variation and
issues with controls downregulating tyrosine hydroxylase, although we
successfully recapitulated the loss and behavioural deficits observed
previously. Additionally, we gained insight from CDNF studies that CDNF can
prevent uptake, modulate aggregation, and ameliorate functional deficits
caused by alpha-synuclein aggregation.
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1 INTRODUCTION
α-synuclein (α-syn) is a 140 amino acids long protein present
throughout the brains and blood of vertebrates. Its function in the central
nervous system remains somewhat elusive, however, over 20 years ago it was
found that a mutation in its gene, SNCA, resulted in an autosomal dominant
form of Parkinson’s disease (Polymeropoulos et al., 1996). This, coupled with
the finding that the major component of Lewy bodies, clumps of protein
found in post mortem brains of Parkinson’s patients, is α-syn (Spillantini et
al., 1997) has made it a central focus in Parkinson’s disease research.
Parkinson’s disease is characterized by the loss of dopamine neurons,
cells that produce the neurotransmitter dopamine, in the substantia nigra
pars compacta and the onset of motor symptoms. Why these neurons die and
result in the core motor symptoms: tremor, rigidity, bradykinesia, and
postural instability, is still unknown. Though Parkinson’s is a multifaceted
disease with other neuronal systems being affected that result in non-motor
symptoms, some which precede the motor syndrome (Hely et al., 2005).
Parkinson’s disease is considered a neurodegenerative disease with the main
risk factor being age. As there is currently only symptomatic treatment
available for the disease, there has been a continual effort to develop a cure.
While the presence of abnormal accumulations of α-syn is a key aspect
of Parkinson’s disease, it is still unknown how, or even if, it is truly related to
disease progression. This enigmatic protein has been used to model the
disease in a variety of situations, from cells to animals it has been knocked
out, overexpressed, or mutated – still, there are many unanswered questions.
However, there are existing models that somewhat recapitulate the human
sporadic form of Parkinson’s disease that can, and have, been used for testing
therapies.
Cerebral dopamine neurotrophic factor (CDNF) was discovered in the
laboratory of Professor Mart Saarma (Lindholm et al., 2007). Since then it
has been tested in animal models of Parkinson’s disease, amongst others, and
is currently in clinical trials for the disease. CDNF is a protein with
neurotrophic-like properties that may be related to an important piece of
cellular machinery: the endoplasmic reticulum. CDNF’s mechanism of action
is still unknown however, and while it has been effective in Parkinson’s
animal models, its effects in animal models of α-syn-based Parkinson’s
disease have not been studied.
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2 REVIEW OF THE LITERATURE
2.1 PARKINSON’S DISEASE
Parkinson’s disease is the second most common neurodegenerative
disorder after Alzheimer’s disease, and the most common of the
neurodegenerative movement disorders. Currently, over 10 million people
worldwide are living with Parkinson’s (Parkinson's Parkinson's Foundation,
2018). The idiopathic form of Parkinson’s disease is primarily a disease of
ageing, where the majority of patients are over 65 at the time of diagnosis (de
Lau et al., 2004). Approximately 10-15% of cases are genetic and do not
necessarily depend on age but rather specific gene mutations, whereas the
other 85-90% of cases are sporadic (de Lau & Breteler, 2006). The disease is
characterized by both motor and non-motor symptoms, and it is most often
diagnosed when motor symptoms manifest. However, there are currently no
disease-modifying therapies, only symptomatic treatment. Since it was first
described in detail in the seminal essay by James Parkinson, An Essay on the
Shaking Palsy (original publication 1817; reprinted (Parkinson, 2002)),
researchers worldwide have put a large amount of effort into studying the
disease pathology and attempting to stop the progression. Parkinson’s disease
pathology is intimately linked with one protein in particular: α-synuclein (α-
syn). α-syn is known to aggregate in Parkinson’s and form inclusions in the
brain called Lewy bodies and neurites which may contribute to
neurotransmission dysfunction and consequent cell death (Spillantini et al.,
1997). These Lewy bodies are present in the brains of almost all patients post
mortem (Gibb & Lees, 1988). Importantly, what defines all Parkinson’s
disease patients is the loss of dopamine neurons in the nigrostriatal system.
2.1.1 DOPAMINE NEURON DEGENERATION IN PARKINSON’S
DISEASE
The nigrostriatal system consists of two primary structures: the
putamen, or dorsal striatum in rodents, and the substantia nigra, which are
connected in the brain by a bundle of dopamine neurons (Hattori, 1993). In
Parkinson’s disease, it is the dopamine neurons of the substantia nigra pars
compacta that degenerate and cause the primary motor symptoms of the
disease. These cardinal motor symptoms include tremor, rigidity, postural
instability, as well as slowness of movement and difficulty initiating
movement (Litvan, 1998). When the substantia nigra dopamine neurons die
they consequently reduce dopamine terminals in the striatum (Scherman et
al., 1989). At the point of motor symptom manifestation however,
approximately 30% of the neurons have already died in the substantia nigra
and up to 60% of the dopamine terminals have been lost in the striatum
(Cheng et al., 2010), therefore this death is considered to occur in a “dying
back” manner, where the axons degenerate first. Additionally, at this time
point there is approximately 70-80% loss of dopamine content in the caudate
putamen. Figure 1A shows a schematic of dopamine neuron loss in the
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substantia nigra pars compacta that leads to loss of fibres connected to the
caudate putamen in a healthy and Parkinson’s brain. The nigrostriatal
pathway is mainly responsible for voluntary movement and the suppression
of involuntary movement, therefore it is no surprise that the motor symptoms
of Parkinson’s appear as such when these neurons degenerate. More
specifically, the substantia nigra sends input to the striatum via dopamine
neurons, which is part of the basal ganglia, a structure responsible for goal-
directed behaviour, among others. Post-synaptic GABAergic medium spiny
neurons that project directly from the substantia nigra to the striatum that
mainly express dopamine 1 (D1) receptors make up the “direct pathway” and
produce intrinsic excitability. Whereas GABAergic medium spiny neurons
that interface indirectly to the basal ganglia and mainly express D2 receptors
make up the “indirect pathway”, which reduces intrinsic excitability
(Surmeier et al., 2014). Figure 1B shows a simplified cartoon diagram of this
circuitry in the rodent brain. These pathways are thought to work in concert
to both activate and suppress movement via dopaminergic input (Cui et al.,
2013).
Figure 1. (A) Schematic diagram of a healthy brain where the substantia nigra pars compacta
(SNpc) dopamine neurons are intact (black arrows), and the pathway to the caudate putamen, the
nigrostriatal pathway, is also intact (red connecting lines); the Parkinson’s disease diagram shows
that the dopamine neurons of the substantia nigra pars compacta are lost and the nigrostriatal
pathway degenerates (dotted red line). Modified from (Dauer & Przedborski, 2003); reprinted with
permission from the copyright holder. (B) Diagram of the rodent brain connections for the direct
and indirect pathways between the substantia nigra and striatum showing dopamine neuronal
connections (blue), GABAergic neuronal connections (red), as well as glutamatergic (green)
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neuronal connections. D1 receptor GABAergic neurons that synapse onto the internal globus
pallidus (GPi) make up the direct pathway, and D2 receptor GABAergic neurons that synapse
onto the external globus pallidus (GPe) make up the indirect pathway. SNr=substantia nigra
reticulate, STN=subthalamic nucleus, PPN=pendunculopontine nucleus. Modified from (Gerfen &
Surmeier, 2011); reprinted with permission from the copyright holder.
The progressive death of substantia nigra dopamine neurons has led
researchers to ask why they are the most vulnerable, particularly when the
adjacent dopamine neurons of the ventral tegmental area (VTA) show more
resilience in Parkinson’s disease (Alberico et al., 2015), and other dopamine
neurons such as those in the hypothalamus show no loss in patients (Matzuk
& Saper, 1985). Although the neurotransmitter dopamine itself may be a
contributing factor to this vulnerability due to the fact that it is rapidly
oxidized and may lead to increased free radicals and further mitochondrial
dysfunction (Berman & Hastings, 1999), it is clear that it is not the only factor
since dopamine neuron death in Parkinson’s disease is not happening
globally but rather to specific subsets of cells. A more likely theory relates to
the activity of substantia nigra pars compacta dopamine neurons. These cells
have pacemaking activity, meaning they have slow intrinsic activity (Grace &
Bunney, 1983; 1984b) which is most likely used to keep levels of dopamine
around a certain threshold. Additionally, burst firing of these neurons occurs
via excitatory stimuli and may affect dopamine release in the striatum (Grace
& Bunney, 1984a). Put simply, both the pacemaking and burst activity
requires calcium ion (Ca2+) currents to be constantly in flux in these cells,
requiring high amounts of ATP and therefore well-functioning mitochondria
(Surmeier et al., 2011; Surmeier & Schumacker, 2013). In Parkinson’s
disease, mitochondria are known to be dysfunctional (Mizuno et al., 1989)
and therefore any excessive bioenergetic load may be even more detrimental.
Also, it is important to note that in normal ageing, there is an increase in
mutations in mitochondrial DNA (Prtenjaca & Hill, 2011), and age is a top
risk factor in Parkinson’s. Additionally, levels of Ca2+ itself can induce
oxidative stress (Sulzer, 2007), and it has been shown that substantia nigra
dopamine neurons have a low capacity to buffer against high levels of Ca2+
(Foehring et al., 2009). It has been shown experimentally that dopaminergic
neurons of the substantia nigra pars compacta differ from dopaminergic
neurons of the VTA area in that they require more energy, have more
mitochondria, have higher production of reactive oxygen species (Pacelli et
al., 2015), and that they have a complex set of axons with a large number of
terminals (Matsuda et al., 2009; Pacelli et al., 2015). This high energy
demand due to the pacemaking activity and axonal arborization, as well as
other potentials for reactive oxygen species, make these neurons more prone
to stressors. This can include endoplasmic reticulum (ER) stress and
dysfunction in proteasome degradation pathways due to protein buildup (Ryu
et al., 2002; Holtz & O'Malley, 2003) or environmental toxins (Tanner &
Langston, 1990), which are linked to Parkinson’s disease. Dopamine neurons
of the substantia nigra pars compacta also exhibit Lewy pathology which may
precede cell death, discussed in greater detail later. In general, the
vulnerability of substantia nigra dopamine neurons to internal and external
stress may be the reason they are preferentially degenerating in Parkinson’s
disease.
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2.1.2 OTHER NEURONS INVOLVED IN PARKINSON’S DISEASE
Dopamine neurons are not the only neurons that degenerate in
Parkinson’s disease — other affected neurons include the dorsal motor
nucleus of the vagus, locus coeruleus, raphe nuclei, basal forebrain, nucleus
basilus of Meynert, enteric neurons, and olfactory bulb (Sulzer & Surmeier,
2013). Interestingly, the neurons of these areas also show pacemaking activity
(Kang & Kitai, 1990; Goldberg et al., 2012; Sanchez-Padilla et al., 2014), and
some exhibit complex axon branching similar to the dopamine neurons of the
substantia nigra pars compacta (Surmeier et al., 2017b). These areas of the
central nervous system, as well as parts of the peripheral nervous system, also
present Lewy pathology. This is important since it relates to the non-motor
symptoms of Parkinson’s disease, which are not only important clinical
features but may precede motor symptoms (Schapira et al., 2017). Table 1
shows affected areas and their corresponding symptom in the disease, in all
cases there has been evidence of Lewy pathology (Dickson et al., 2009).
Table 1. A simplified table of areas of the nervous system that are mainly affected in Parkinson’s
disease and their corresponding non-motor symptoms.
Brain area Neurons affected Symptom Reference
Dorsal motor
nucleus of the vagus
Sympathetic ganglia,
enteric neurons*
Gastrointestinal
dysfunction (ex.
constipation)
(Greene, 2014)
Olfactory bulb Mitral cells Olfactory dysfunction
(reduction or loss of
smell)
(Pearce et al., 1995)
Locus coeruleus Noradrenergic
neurons
Depression (Frisina et al., 2009)
Basal forebrain Cholinergic neurons* Cognitive defects and
dementia
(Nakano & Hirano,
1984)
Brain stem,
hypothalamus,
cortex
Noradrenergic,
serotonergic neurons*
REM sleep disorder (Boeve et al., 2007)
Cortical layers,
hippocampus
Cholinergic neurons* Dementia (Halliday et al.,
2014)
(Hall et al., 2014)
*dopamine neurons are also affected
The non-motor symptoms in Table 1 are the often mentioned
prodromal symptoms of Parkinson’s disease (Schapira & Tolosa, 2010), for
example, olfactory deficits are observed in 90% of Parkinson’s patients prior
to a definitive diagnosis (Bohnen et al., 2008). Although others, such as
cognitive decline, may come after the disease diagnosis (Aarsland et al.,
2003). Additionally, it is evident that these symptoms are generally not
alleviated by current dopamine-related treatments and in fact may
compromise a patient’s quality of life more so than the motor symptoms
(Hely et al., 2005). Therefore, the non-motor symptoms of Parkinson’s
disease represent an important area for future disease therapy.
2.1.3 CURRENT TREATMENTS IN PARKINSON’S DISEASE
As mentioned, there is currently only symptomatic treatment for
Parkinson’s disease and no intervention has been able to accomplish
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significant disease progression modification. Though there have been
successful ways of alleviating symptoms, and in particular drugs that increase
dopamine in the brain or deep brain stimulation have been extensively
utilized.
ʟ-DOPA (ʟ-3,4-dihydroxyphenylalanine), or levodopa, is one of the
most common therapies for Parkinson’s patients and is recommended
throughout the disease. It can be taken orally or via infusion pump to the
jejunum since it crosses the blood-brain barrier and once it enters the brain it
is converted to dopamine by aromatic ʟ-amino acid decarboxylase (other
names include dopa decarboxylase) (Birkmayer & Hornykiewicz, 1998).
Though higher doses are associated with dyskinesia, it is still widely used to
treat the motor symptoms of Parkinson’s disease (Birkmayer & Hornykiewicz,
2001). Additionally, dopa decarboxylase inhibitors and catechol-O-
methyltransferase (COMT) inhibitors are used as adjunct therapies with
levodopa to reduce its side effects and increase its efficacy, respectively. Since
orally taken levodopa metabolizes rapidly in the periphery, resulting in
circulating dopamine, this causes side effects. Therefore, combination with a
dopa decarboxylase inhibitor is used to counteract this as it will inhibit
metabolization of levodopa into dopamine; this only occurs in the periphery
and not in the brain since dopa decarboxylase inhibitors do not cross the
blood-brain barrier (Thanvi & Lo, 2004). However, when dopa decarboxylase
is inhibited, other enzymes may compensate, therefore COMT inhibitors are
used as an additional drug (Mannisto & Kaakkola, 1990). COMT inhibitors
act to increase the bioavailability of levodopa and consequently increase
dopamine levels in the striatum (Mannisto et al., 1988). Dopamine agonists
are also used as a therapy to increase dopamine and alleviate motor
symptoms either alone or in combination with levodopa (Shannon et al.,
1997). However, these agonists act on dopamine receptors in the periphery
and may induce more severe side effects (Weintraub et al., 2006), and in
general levodopa is more commonly used (LeWitt, 2008).
In addition to dopamine system-related therapies it should be
mentioned that there are several other classes of drugs that have been tested
in Parkinson’s patients. Adenosine (Bara-Jimenez et al., 2003; Factor et al.,
2013), adrenergic (LeWitt et al., 2012) and glutamate receptor antagonists
(Emre et al., 2010; Kobylecki et al., 2014; Wang et al., 2018), serotonin
receptor agonists (Goetz et al., 2007), Ca2+ channel blockers (Rees et al.,
2011; Parkinson Study Group, 2013), a glucagon-like peptide agonist
(Athauda et al., 2017), iron chelators (Devos et al., 2014), and anti-
inflammatory compounds (Ninds Net-Pd Investigators, 2008) have all been
tested in small to large groups of patients with some success on symptoms of
the disease.
Deep brain stimulation is a surgical procedure approved to treat
Parkinson’s disease that involves implanting a device into the internal globus
pallidus, subthalamic nucleus (STN), or ventral intermediate nucleus of the
thalamus to stimulate these areas electrically; the area of implantation
depends on the primary symptom the physician aims to alleviate
(Kringelbach et al., 2007). Deep brain stimulation has the advantage of being
both controlled and reversible, adding safety to efficacy. Its use results in
positive effects on motor symptoms of Parkinson’s disease patients,
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particularly since it is mostly used in those who are resistant to dopamine
replacement therapy.
2.1.4 PROGRESS IN PARKINSON’S DISEASE-MODIFYING THERAPY
In addition to these established forms of treatment, other strategies
have been developed to accomplish dopamine neuron restoration that not
only alleviates symptoms but also stops or reverses disease progression. One
avenue has been the use of stem cells which were successful in animals
(Svendsen et al., 1997) and are currently in or have been in clinical trials
(Barker et al., 2017). More specifically, midbrain dopamine neuron
progenitors are derived from embryonic stem cells or induced pluripotent
stem cells and implanted into the striatum of patients (Polgar et al., 2003).
Although immunosuppression is needed in human patients to prevent the
rejection of these cells by the immune system, and tumorigenesis is also a
concern (Olanow et al., 2003). Also, a well-known outcome in the field was
the result that grafted dopamine neurons in the Parkinsonian patients’ brains
began to develop Lewy pathology (Kordower et al., 2008; Li et al., 2008).
Therefore, while stem cell therapy is potentially promising since there are
several ongoing clinical trials (NCT02538315, 2015; NCT03309514, 2017),
caution needs to be taken.
Gene therapy with adeno-associated viral (AAV) vectors is another line
of research that has brought potential new treatments to clinical trials for
Parkinson’s disease. The safety of AAVs is clear since they are non-replicating
vectors that have not shown an inflammatory response (Vandendriessche et
al., 2007), and they can maintain long-term expression in neurons, therefore
making them an optimal choice for therapy in human diseases (Lim et al.,
2010). Two proteins in particular have been important for Parkinson’s
disease treatment in order to alleviate symptoms and restore dopamine
neurons: glial cell line-derived neurotrophic factor (GDNF) and its related
factor neurturin (NRTN). These are neurotrophic factors, proteins that both
regulate growth of developing neurons and continue to maintain adult
neurons, as well as showing protection and repair of damaged neurons in
animals (Airaksinen & Saarma, 2002). Administration of AAV-GDNF to the
striatum was able to restore motor behaviour and dopamine neurons of the
nigrostriatal system in a rat toxin model of Parkinson’s disease (Wang et al.,
2002) and delivery to the substantia nigra of monkeys showed positive effects
on the dopaminergic system (Johnston et al., 2009). Currently, AAV2-GDNF
is in a clinical trial for Parkinson’s disease (NCT01621581, 2012); previously,
infusion of the protein alone to the putamen has yielded mixed results due to
the protein not being able to reach dopamine neurons or problems with
delivery, but in general, GDNF seems to have a positive effect on symptoms
and outcome (Nutt et al., 2003; Lang et al., 2006). AAV-NRTN, a
neurotrophic factor in the same family as GDNF (Airaksinen & Saarma,
2002), has also been studied extensively for Parkinson’s disease. AAV2-
NRTN was successfully tested in rats in terms of safety and protection in a
toxin model of Parkinson’s disease (Bartus et al., 2011a). Two trials were
conducted: AAV-NRTN was delivered to the putamen alone (Marks et al.,
2010) or to both the putamen and substantia nigra (Olanow et al., 2015).
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However, neither trial showed benefits of NRTN over sham surgery –
although a later analysis indicated that patients with an earlier diagnosis had
a more positive response than those diagnosed later (Bartus & Johnson,
2017). Additionally, there are ongoing clinical trials for AAV-aromatic L-
amino acid decarboxylase (AADC) (NCT02418598, 2015) and a previous trial
for AAV-glutamic acid decarboxylase (LeWitt et al., 2011) that have shown
promise as a treatment for Parkinson’s disease. However, the question of
whether AAV injection to the striatum, substantia nigra, or both needs to be
carefully considered since when the nigrostriatal system degenerates it begins
with the axons of the striatum and continues to the cell bodies of the
substantia nigra. Also, spreading of the protein using AAV delivery needs to
be considered (Bartus et al., 2011a): In the previous AAV2-NRTN trial, the
coverage estimation was 20% of the putamen (Bartus et al., 2011b), and in the
previous AAV-AADC trial distribution of the enzyme was estimated at
approximately 25% of the putamen (Mittermeyer et al., 2012). In general,
however, the safety and long-lasting expression of AAVs has made them
promising avenues for not only symptomatic treatment, but also as a disease-
modifying therapy. And while using drugs and surgical intervention has been
of great benefit for Parkinson’s disease treatment, researchers, physicians,
and patients continue to search for a cure.
2.1.5 GENETIC FORMS OF PARKINSON’S DISEASE
Though the majority of Parkinson’s cases are sporadic, a small portion
have a genetic cause. These are monogenic forms that arise from the
mutation, either dominant or recessive, of a single gene. There are currently
17 identified PARK chromosomal loci mutations which have been confirmed
to result in a Parkinsonian phenotype, (Klein & Westenberger, 2012), and in
total 26 loci have been identified as a risk of developing Parkinson’s disease
(Lill, 2016). For the purpose of this thesis only the 6 that have the clearest
evidence as being linked to monogenic and heritable Parkinson’s disease will
be discussed.
LRRK2 (leucine-rich repeat kinase 2; PARK8) mutations are the most
common autosomal-dominant, as well as the genetic cause of sporadic, form
of Parkinson’s disease (Lesage et al., 2006; Ozelius et al., 2006). This form is
mid-to-late onset and does not always present with Lewy pathology (Giasson
et al., 2006). Parkin (PARK2) causes an autosomal-recessive form of the
disease and often begins when the patient is 30-40 years old; homozygous
carriers can show onset before 21 years of age (Kitada et al., 1998). Parkin
patients are mostly lacking Lewy bodies. PINK1 (phosphatase and tensin
homolog (PTEN)-induced putative kinase 1; PARK6) is the second most
frequent autosomal-recessive form with a phenotype similar to Parkin. Most
PINK1 mutations are loss-of-function and may work in concert with Parkin to
induce mitophagy (Valente et al., 2004). DJ-1 (deglycase, PARK7) is also
autosomal recessive and presents similarly to both Parkin and PINK1 with
early onset Parkinson’s disease, though this is the rarest of the three (Bonifati
et al., 2003). Less is known about DJ-1 but it has been shown that the
mutated form does not fold properly and is degraded quickly (Moore et al.,
2003). Autosomal recessive mutations in ATP13A2 (PARK9) have been
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demonstrated to result in juvenile onset Parkinson’s that progresses quickly,
it also presents with other symptoms and is known as Kufor-Rakeb syndrome
(Ramirez et al., 2006).
Last, but not least, is the SNCA (PARK1/4) mutation. Mutations in
SNCA cause autosomal dominant Parkinson’s disease that has an onset of less
than 50 years of age (Polymeropoulos et al., 1996). This form of the disease
progresses quickly and shows Lewy pathology that spreads throughout
similarly affected brain areas in sporadic Parkinson’s such as the substantia
nigra and locus coeruleus (Polymeropoulos et al., 1996). SNCA is in fact the
gene coding the α-syn protein and duplications (Chartier-Harlin et al., 2004)
and triplications (Singleton et al., 2003) of SNCA result in Parkinson’s of
increasing severity (Fuchs et al., 2007). In general, though the genetic forms
of Parkinson’s disease are far less common, discovering these genes and their
effects have given valuable information about disease aetiology.
2.2 ALPHA-SYNUCLEIN
As mentioned, genetic mutations of the SNCA gene result in an
autosomal dominant form of Parkinson’s disease, and α-syn is the main
component of Lewy bodies (Spillantini et al., 1997), which are found in
almost every idiopathic case of the disease (Gibb & Lees, 1989). α-syn is
present in healthy humans but has become an extensively studied protein in
relation to Parkinson’s disease for the above reasons. Since α-syn is
considered the main pathogenic protein of Parkinson’s disease a majority of
research focus has been placed on it.
2.2.1 ALPHA-SYNUCLEIN FUNCTION AND KNOCKOUT MODELS
Synuclein was first isolated from the cholinergic vesicles at the synapse
and nuclear envelope of Torpedo (Maroteaux et al., 1988), thus the name
“synuclein”. It was also found in the zebra finch where it functions in song
learning (George et al., 1995), pointing to a potential role in synaptic
plasticity. Both of these proteins were found to be the homologue of human
α-syn and along with β- and γ-synuclein it makes up the synuclein family
(Jakes et al., 1994). α-syn is a 140 amino acid protein that is present
throughout the central and peripheral nervous systems, though it is also
present in red blood cells (Barbour et al., 2008). α-syn is an abundant
protein, being 1% of all cytosolic protein in the brain (Stefanis, 2012). More
specifically, it is localized at the nerve terminal: a study using transgenic mice
expressing human wild-type α-syn fused to green fluorescent protein (GFP)
were imaged in vivo with multiphoton microscopy. The authors were able to
visualize neurons in the live mouse brain and determine that the majority of
α-syn was located at presynaptic terminals (Unni et al., 2010). This has
already been shown similarly in humans; healthy human brain sections were
immunostained for α-syn and synaptophysin, a synaptic vesicle protein, and
it was observed that they colocalized in neurons (Kahle et al., 2000).
α-syn’s localization at the synapse has been known for over 20 years,
however its normal function has not been completely elucidated – though it
seems to be related to the SNARE complex, which plays a crucial role in
Review of the Literature
10
neurotransmitter release (Sudhof, 2013). It has several known interacting
proteins at the presynaptic terminal: synaptobrevin-2 (Burre et al., 2010),
synapsin III (Zaltieri et al., 2015), synphilin (Engelender et al., 1999; McLean
et al., 2001; Ribeiro et al., 2002), vesicular monoamine transporter 2
(VMAT2) (Guo et al., 2008), dopamine transporter (DAT) (Butler et al.,
2015), and serotonin transporter (Wersinger et al., 2006). It also regulates
tyrosine hydroxylase (TH) (Perez et al., 2002), the rate-limiting enzyme of
dopamine and other catecholamine synthesis, and the membrane interaction
of Rab3 (Chen et al., 2013). Additionally, it binds to DJ-1 (Zondler et al.,
2014), as well as tubulin to regulate microtubules (Lee et al., 2006). Lastly, it
has been found to enhance phosphorylation of tau, a protein also involved in
Alzheimer’s disease (Jensen et al., 1999; Haggerty et al., 2011). There are also
suggested roles of α-syn in lipid transport (Fortin et al., 2004). However,
since there is no α-syn in non-vertebrates (ex. Saccharomyces, Drosophila, or
C. elegans) (George, 2002), this has made it difficult to ascertain the precise
function and true importance of this protein.
One of the most common and useful tools for determining a protein’s
function in vivo is by studying knockout (KO) animals, where the protein is
either removed completely or in a specific tissue from an animal. Since α-syn
has a plethora of binding proteins and seems to be important in synaptic
transmission, naturally a mouse KO was expected to have clear deficits in, for
example, neurotransmitter release and/or synaptic plasticity. There have
been single α-syn KO, double KO of α+β-syn, and triple KO of α+β+γ-syn in
mice. However, the deficits have not been so pronounced. The single KO mice
have reduced dopamine content in the striatum and amphetamine-induced
locomotor activity, though interestingly, they displayed a faster recovery of
dopamine release. Although, they are viable and do not show loss of
nigrostriatal dopamine neurons (Abeliovich et al., 2000). By contrast, a
different group showed that deletion of the SNCA gene resulted in fewer TH+
neurons in the substantia nigra during mouse development (Garcia-
Reitboeck et al., 2013). In another single KO study, the authors also found
that the mice had a lower capacity of dopamine storage, but that there was an
increased rate of refilling of the readily releasable pool of vesicles, possibly
acting as a compensatory mechanism (Yavich et al., 2004). The double and
triple KO mice were bred to account for possible compensation in the nervous
system by β- and γ-syn. In the double KO for α+β-syn, mice were also viable
and fertile (Chandra et al., 2004). As with the single α-syn KO, there were no
gross changes in the brain and importantly the number of TH+ cells in the
substantia nigra was similar to wild-type littermates. Although striatal levels
of dopamine were decreased as well. In general, there were no significant
changes of the synapses or vesicles. A notable change was the increased
protein levels of γ-syn, complexin, and 14-3-3ε, and decrease in of 14-3-3ζ. γ-
syn’s increase, although likely a compensatory mechanism, was considered
not overly interesting since the levels in the adult brain are already low
(Clayton & George, 1998). However, complexin is also a small, presynaptic
protein involved in neurotransmitter release (Reim et al., 2001) and the 14-3-
3 proteins are similar in homology to α-syn (Ostrerova et al., 1999). The triple
synuclein KO mice were similar to wild-type mice in survival and overall
brain architecture (Anwar et al., 2011). There were also no changes in number
of TH+ cells in the substantia nigra pars compacta or VTA, as well as TH
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fibres in the striatum. Synaptic proteins, the SNARE complex, and synapse
morphology were also unchanged. As with the other KO mice, the levels of
striatal dopamine were significantly decreased compared to the wild-type. For
behaviour, the triple KO mice performed worse on an accelerated rotarod and
had increased exploratory activity in a “novel, non-anxiogenic environment”,
the latter of which the authors hypothesize is related to hyperdopaminergic
activity. This could be due to the fact that even though dopamine content was
decreased in the striatum, when dopamine release was stimulated in striatal
slices, the KO had a higher extracellular amount than wild-type mice, which
was not due to faster reuptake. Another behavioural experiment performed
sheds light on this: when amphetamine was given to the KO mice, a drug that
increases extracellular dopamine by reverse transport at the vesicles (Sulzer
et al., 1995), they had reduced stimulated motor activity compared to wild-
type. This could indicate that there is less dopamine in presynaptic vesicles in
the triple synuclein KO. In general, since it is not clear that there would be a
major deficit on the dopamine system of KO mice, it seems that α-syn, and
the rest of the synuclein family, is having a minor effect on dopamine release
resulting in a decrease in overall striatal dopamine. Lastly, a study from Burre
and colleagues (Burre et al., 2010) revealed that α-syn binds to
synaptobrevin-2/VAMP2 to enhance SNARE complex assembly. Further, the
authors used the triple synuclein KO to study in vivo effects and found an
age-dependent neurological deficit, decreased survival, and a significant
decrease in synaptobrevin-2 – in other words, only the aged mice (~1 year)
exhibited these characteristics, implicating synucleins in neuronal function
over time. From these interaction and KO studies, it is clear that α-syn is
functioning at the presynaptic cleft and this may be where its involvement
with dopamine neurotransmission is the most important.
2.2.2 ALPHA-SYNUCLEIN AND DOPAMINE
As discussed above, α-syn interacts with various proteins related to
dopamine and a marked decrease of striatal dopamine content is observed in
the KO mice. Importantly, through its direct interaction with TH, it was
shown that in a dopaminergic cell line (MN9D) where α-syn was
overexpressed, there was a decrease in TH activity which resulted in reduced
dopamine synthesis; this effect occurred without a decrease in overall TH
protein level (Perez et al., 2002). The mechanism of TH activity reduction
was via decrease in phosphorylation of Ser40 after overexpression of α-syn in
MN9D cells, where phosphorylation of Ser40 on TH is considered to
significantly contribute to dopamine synthesis (Peng et al., 2005). To
complement the in vitro studies, studies have found that there is an age-
dependent relationship between α-syn and TH in healthy humans and
monkeys, where TH decreases over time whereas α-syn increases over time in
the soma of nigral neurons (Chu & Kordower, 2007).
α-syn’s interaction with VMAT2 has also been explored further using
overexpression vectors in mice. α-syn was overexpressed in the substantia
nigra neurons of mice that were deficient in VMAT2, and this resulted in
increased dopamine degeneration compared to wild-type, which was reversed
by silencing of TH (Ulusoy et al., 2012). The hypothesized mechanism of this
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finding is that since VMAT2’s normal function is to sequester dopamine to
reduce its oxidation, the reduction in VMAT2 led to an increase in dopamine
in the substantia nigra neurons, thus causing cell death due to higher
amounts of dopamine being present. Since this effect was reversed by loss of
TH, thereby bringing the amount of dopamine closer to normal levels, it
stands to reason that dopamine itself was causing more severe
neurodegeneration in the mice. However, this theory is difficult to rectify with
current knowledge since levodopa has not shown clear indication of increased
disease progression in Parkinsonian patients (Olanow, 2015).
In addition to VMAT2, DAT as an interaction partner of α-syn has
been studied but the results have been conflicting for the exact outcome
(Butler et al., 2017). DAT has been shown to interact with α-syn, including in
in vivo studies using a proximity ligation assay (PLA) that detects protein-
protein interactions (Bellucci et al., 2011a). DAT is an important protein that
regulates dopamine levels in the brain by removing it from the extracellular
space and replenishing it in the neuron, thus DAT is able to both terminate
dopamine neurotransmission and maintain it at the synapse. An in vitro
study has shown that increasing levels of α-syn results in decreased uptake of
dopamine via DAT (Swant et al., 2011). This was also demonstrated in vivo
where authors injected E. coli-produced recombinant human α-syn directly
into the striatum of α-syn KO mice and observed a decrease in dopamine
uptake as well as evoked overflow six days after injection, likely related to
DAT (Pelkonen et al., 2013). Related to this, in a mouse model overexpressing
α-syn, there was a significant increase in striatal dopamine in the mutant
mice compared to the wild-type mice at six months of age, which resulted in
decreased dopamine tissue content and TH expression in the striatum at
fourteen months old. Although this was not necessarily related to DAT since
reuptake was unchanged between the genotypes (Lam et al., 2011).
Additionally, there has been a conflicting report of the α-syn-DAT outcome:
that DAT actually increases dopamine uptake when human α-syn and human
DAT are co-expressed in cells (Lee et al., 2001). In general, α-syn’s links to
dopamine at the presynaptic cleft continues to be a focus for researchers,
however it is still not known exactly how these interactions may be relevant to
dopamine neuron death or modulation of neurotransmission in Parkinson’s
disease.
2.2.3 ALPHA-SYNUCLEIN STRUCTURE
The structure of α-syn has received attention for a number of reasons.
Different parts of the α-syn protein contribute to its various aggregation,
functional, and binding properties, also post-translational modifications and
mutations of the protein are important, particularly in disease. Additionally,
there has been debate in the field about the physiological structure of α-syn
and how it may contribute to aggregation and neuronal dysfunction. A widely
cited view is that α-syn exists in an equilibrium between two states in the
brain: it is natively unfolded in the cytosol (Burre et al., 2013), but in a
helical, multimeric state when bound to membranes (Burre et al., 2014). This
theory posits that α-syn mainly exists as a monomeric 14 kDa protein that is
intrinsically disordered and prone to aggregation. However, this theory has
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been criticized due to the fact that these experiments were performed using
recombinant α-syn protein purified using E. coli systems with sample heating
and/or denaturing, which may not represent relevant physiological
conditions; and it is well-known that proteins produced in E. coli are often
not folded as they would normally be in vivo. Therefore, when researchers
used samples of brain tissue, human cells, and cell lines without denaturation
they found that α-syn principally occurred as a folded tetramer of
approximately 58 kDa in size (Bartels et al., 2011). To add to this, it was
found that tetrameric α-syn has vesicle trafficking functions at the synapse
under normal conditions (Wang et al., 2014). Therefore, in opposition to the
above theory, researchers hypothesize that α-syn rather exists more often as
an α-helical folded tetramer in equilibrium with the unfolded monomer, and
that the tetramer is resistant to aggregation. To avoid confusion in this thesis,
I have defined the terms in Box 1 which shows a list of glossary terms used
here when referring to α-syn structure throughout.
The N-terminal region of monomeric α-syn contains an amphipathic
α-helix formed by an 11-residue repeat sequence related to phospholipid
membrane binding (Bussell & Eliezer, 2003), and it is here that the missense
mutations are occurring. The acidic C-terminus consists of mostly glutamate
and is generally where most of the protein interactions take place, as well as
protection from aggregation (Murray et al., 2003) (Figure 2). In between the
N- and C-termini is the non-amyloid-β component of Alzheimer’s disease
amyloid (NAC) region, so named since it was first purified in amyloid plaques
of Alzheimer’s patients. It consists of a 35 amino acid sequence that is
hydrophobic, and the human form is prone to aggregation, but interestingly
not the mouse (Ueda et al., 1993). Figure 2 represents the schematic sequence
of α-syn. In addition to its normal structure under physiological conditions,
during pathological conditions it can adopt a β-sheet formation that is related
to aggregation, fibril formation, as well as Lewy bodies (Rochet et al., 2000;
Ding et al., 2002).
These pathological conditions can come from overexpression or high
amounts of α-syn or from mutations of the protein. The following missense
mutations have been found in α-syn to cause Parkinson’s disease: A30P
(Kruger et al., 1998), E46K (Zarranz et al., 2004), H50Q (Proukakis et al.,
2013), G51D (Kiely et al., 2013), A53E (Pasanen et al., 2014), and A53T
(Polymeropoulos et al., 1997). In addition to confirming α-syn’s importance
in Parkinson’s disease, their use in modeling the disease has become an
important tool.
Another structural aspect of α-syn is its forming of oligomers or fibrils.
The formation of α-syn aggregates is considered to occur by natively unfolded
α-syn monomers forming intermediate aggregated oligomers, and then these
Box 1. α-synuclein structure terms.
monomer 14 kDa protein, unfolded, prone to aggregate
tetramer 58-60 kDa protein, α-helical folded, resists aggregation
oligomer 60+ kDa protein, may cause cell dysfunction if misfolded
fibril fibrillar, β-sheet structure, considered aggregate and may cause cell dysfunction
Lewy body cluster of proteins, of which α-synuclein is the main component
or neurite
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form into insoluble fibrils, the latter being toxic as it builds up (Fink, 2006).
Fibrillization of α-syn is considered the main aggregation form in Parkinson’s
disease. However, the formation of oligomer intermediates is also considered
an important step in the process, and this form may be equally or even more
detrimental than the fibrillar form when the oligomer is misfolded. Oligomers
in this case being approximately 80 kDa in size, in other words larger than
the approximate 60 kDa tetramer (Dettmer et al., 2013). Studies have shown
that these oligomers can cause cell death in vitro after transfection of the cells
and in non-mammalian models using expression vectors of α-syn (Danzer et
al., 2007; Karpinar et al., 2009). In rodents, loss of TH in the substantia
nigra neurons was demonstrated when mutant α-syn that favours oligomer
formation was injected into the substantia nigra via lentiviral vector (Winner
et al., 2011), and in a mouse model that received α-syn oligomers directly to
the brain showed motor and non-motor deficits, as well as olfactory and
dopamine degeneration (Fortuna et al., 2017). As well, a study in transgenic
mice with a mutation that preferentially forms oligomers had defects in
synaptic function, loss of dendritic spines, and some behavioural deficits
(Rockenstein et al., 2014). However, others have shown that fibrils are in fact
the most harmful strain of α-syn (Peelaerts et al., 2015). In relation to this,
the tetrameric form must also be considered. When the levels of monomers
that go on to form insoluble aggregates increases, the levels of tetramers
decrease: this can be achieved by mutations that decrease the
tetramer:monomer ratio and may lead to disease initiation (Dettmer et al.,
2015). In fact, this was demonstrated in a mouse model where mutations that
shifted tetrameric α-syn to monomeric α-syn resulted in insoluble inclusions,
a motor syndrome where mice showed abnormal gait and tremor, and some
degeneration in the nigrostriatal dopamine system (Nuber et al., 2018).
Although interestingly, in this model the pathology was not only in the
striatum and midbrain, but also observed in the cortex, indicating that
cortical layers and/or their connections may also be involved in motor
symptoms. Additionally, α-syn can undergo several post-translational
modifications. These are summarized in Table 2.
Figure 2. A simplified schematic sequence of α-synuclein showing the N- and C-termini as well as
the NAC region. Common mutations are also indicated. Modified from (Stefanis, 2012); reprinted
with permission from the copyright holder, Cold Spring Harbor Laboratory Press.
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Table 2. A summary of α-synuclein posttranslational modifications and their proposed function or
outcome.
Modification Location Function Reference
Phosphorylation S87, S129, Y125,
Y133, Y135
Inhibition of
aggregation
(Waxman &
Giasson, 2008)
(Negro et al., 2002)
Acetylation N-terminal Increases membrane
affinity and helical
folding
(Maltsev et al.,
2012)
Ubiquitination Lysine residues (ex.
K21, K23, K32, K34
may be important)
Ubiquitination in
pathological
conditions (ie. Lewy
bodies, neurites)
(Nonaka et al.,
2005)
Glycation Arginine residues
(unpublished
observation)
Glycation end
products have been
observed in
Parkinson’s disease
brains
(Munch et al., 2000)
Glycosylation Residues 53, 64, 72,
87
Unknown; may inhibit
aggregation
(Marotta et al.,
2012)
Nitration Tyrosine residues Nitrated α-syn in
pathological fibrils;
also shown to inhibit
fibril formation
(Giasson et al.,
2000)
(Yamin et al., 2003)
Proteolysis C-terminal truncation Increase aggregation
and fibril assembly
(Serpell et al., 2000)
Phosphorylation of α-syn has been a strong research focus, particularly
phosphorylation at serine 129 (pS129). This is due to the fact that there is
indication that pS129 is present in Lewy bodies (Anderson et al., 2006) and
studies from primates have shown that it is increased during ageing in the
substantia nigra (McCormack et al., 2012). Interestingly, though pS129 α-syn
is present in healthy human brains, particularly in the substantia nigra and
nucleus basalis of Meynert (Muntane et al., 2012), it has been shown to make
up approximately 90% of the α-syn in brains of patients with a
synucleinopathy (Fujiwara et al., 2002). pS129 α-syn has been shown to have
other functions in vitro, however it is still not fully understood whether this
phosphorylation is a toxic event in itself that may increase inclusion
formation or whether it precedes α-syn pathology in the brain (Oueslati et al.,
2010; Oueslati, 2016).
The structure of α-syn plays a critical role in both its normal and
potential pathological functions, making it a continued area of research focus.
Additionally, pS129 α-syn appears to be important not only in Parkinson’s
disease, but also other diseases that are linked to α-syn.
2.2.4 ALPHA-SYNUCLEIN IN NEURODEGENERATIVE DISEASES
While α-syn is normally present in the healthy human brain, its
accumulation in to Lewy bodies and neurites in Parkinson’s as well as
mutations in the SNCA gene are clear indications it is related to the disease.
Additionally, α-syn and Lewy bodies are present in other neurodegenerative
disorders other than Parkinson’s.
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Lewy bodies are mostly α-syn immunoreactive (Spillantini et al.,
1997), but there is also ubiquitin and other proteins present in these
inclusions (Goldman et al., 1983; Kuzuhara et al., 1988; Kawamoto et al.,
2002). They are considered to be the main neuropathological indicator of
Parkinson’s disease since they are found in most patients (Gibb & Lees,
1989), but not all (Berg et al., 2014). Lewy bodies form in the cytoplasm and
neurites in the neurons of the brain, and they have been found throughout the
Parkinsonian brain, including the substantia nigra (Crowther et al., 2000).
Lewy pathology is present throughout the brains of Parkinson’s patients and
appears to spread from one area to another. The most famous
characterization of this comes from Heiko Braak and the staging hypothesis
that he and others postulated (Braak et al., 2003). Braak theorized that over
the time course of the disease Lewy pathology is present in an increasing
number of brain areas, and interestingly that it may initiate in the autonomic
nervous system, more specifically the gut and olfactory system (Hawkes et al.,
2007). Importantly, the brain areas that show pathology are anatomically
connected, so it seems that α-syn pathology is spreading along neuronal
tracts. Further evidence for spreading of α-syn came from the finding that
when fetal dopamine neurons were transplanted to Parkinson’s patients’
brains, these healthy neurons also developed Lewy pathology (Kordower et
al., 2008; Li et al., 2008). This led to the hypothesis of cell-to-cell transfer of
α-syn and further studies in vitro and in vivo to demonstrate this
phenomenon and discover possible mechanisms. Purified fibrils of α-syn
have been used as a tool to elucidate the propagation of the protein and as
such have been quite powerful, as will be discussed below in relation to
models of Parkinson’s disease. However, though there is ample evidence from
models of α-syn spreading, also referred to as the prion hypothesis, how it is
contributing to disease pathology is still unclear. Opponents of the
staging/prion hypothesis point out that only approximately half of patients
have this staging scheme (Kalaitzakis et al., 2008) and that it does not
correlate with disease severity (Jellinger, 2009). Additionally, the areas with
the most severe Lewy pathology do not necessarily transmit large amounts of
α-syn to their connected areas, for example the locus coeruleus (Burke et al.,
2008; Surmeier et al., 2017a). As discussed above, it appears that the
pacemaking and related high energy load of substantia nigra dopamine
neurons makes them vulnerable to stressors in Parkinson’s disease, and that
is what is causing disease pathology. However, though the presence of α-syn
cannot be denied but may instead be a consequence of impaired neuronal
function, rather than the initial trigger of the disease. Evidence of this comes
from observations that cell dysfunction may come before Lewy pathology is
detected, which has been demonstrated with substantia nigra dopamine
neurons (Milber et al., 2012). And as such, impaired autophagy and
lysosomal pathways (Pan et al., 2008; Dehay et al., 2013), ER stress
(Lindholm et al., 2006), proteasomal degradation pathways (Olanow &
McNaught, 2006), have all been implicated in Parkinson’s disease. A diagram
indicating possible contributions to Parkinson’s disease is shown in Figure 3.
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Figure 3. Potential contributions to Parkinson’s disease pathophysiology. Modified from (Surmeier
et al., 2017a); reprinted with permission from the copyright holder.
 The presence of α-syn has also been important in other
neurodegenerative diseases. As mentioned, it has been found in Alzheimer’s
disease (Lippa et al., 1998), and it has been documented in the rare
parkinsonism-dementia complex of Guam (Yamazaki et al., 2000). Though
the most important diseases with Lewy pathology are dementia with Lewy
bodies, Parkinson’s disease with dementia, and multiple system atrophy.
Dementia with Lewy bodies is exactly as it sounds: patients have late-onset
dementia and a high degree of Lewy pathology in the cortical areas (Kosaka,
1978). Interestingly, these are similar to the α-syn-reactive Lewy bodies of the
substantia nigra in Parkinson’s disease patients (Spillantini et al., 1998b).
Parkinson’s disease with dementia is very similar to Parkinson’s disease,
however it includes memory loss accompanied by tau inclusions, which are
far less common in Parkinson’s disease (Burn et al., 2006). This disorder also
has Lewy pathology similar to Parkinson’s (Lippa et al., 2007). Multiple
system atrophy is clinically similar to Parkinson’s disease since the core
symptoms are similar to the motor symptoms observed in it (Lantos, 2001).
Additionally, autonomic symptoms such as incontinence are observed, and
neuropathology is also present in the substantia nigra, striatum, and locus
coeruleus, as well as pontine nuclei, cerebellum, and parts of the spinal cord
(Wakabayashi et al., 1998). A distinctive facet of multiple system of atrophy is
that the α-syn-reactive inclusions are mostly in the glial cells, particularly the
oligodendrocytes (Spillantini et al., 1998a). Together, these diseases are often
referred to as synucleinopathies. These studies have pointed to α-syn as an
important aspect of disease, and how it may relate to progression and severity
continues to be a focus for research.
2.2.5 ALPHA-SYNUCLEIN AND PROTEIN DEGRADATION
Since α-syn is accumulating in disease, but not in the healthy human
brain, this may be occurring due to dysfunction in systems related to protein
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clearance. There are two important systems related to the degradation of
proteins: the ubiquitin-proteasome system and the autophagy-lysosome
pathway, and as mentioned these may be dysfunctional in Parkinson’s disease
as well as other neurodegenerative diseases that have an abnormal buildup of
proteins (Pan et al., 2008).
The ubiquitin-proteasome system is responsible for degrading most
short-lived and misfolded proteins (Martinez-Vicente & Vila, 2013). Briefly,
this system functions by tagging proteins with ubiquitin and then these
tagged proteins are specifically degraded by a proteasome; this system
functions in a highly regulated manner (Finley, 2009). The connection
between the ubiquitin-proteasome system and Parkinson’s disease comes
from both cellular and in vivo models that use a proteasome inhibitor to
induce death of substantia nigra dopamine neurons and buildup of α-syn
(McNaught et al., 2002a; McNaught et al., 2002b). Importantly, mutations in
parkin, which is known to cause a genetic form of Parkinson’s disease, may be
related to dysfunction in degradation of proteins by the proteasome resulting
in impaired α-syn clearance. Parkin is a part of the machinery, the E3
ubiquitin ligase, that adds the ubiquitin chain to proteins to be sent for
degradation by the proteasome (Kitada et al., 1998), and it has been shown
that mutations led to accumulation of α-syn in the human brain (Shimura et
al., 2001). Additionally, α-syn has been shown to interact with one of the
most-studied proteasomes, 26S, and impair its function (Snyder et al., 2003).
There are various ways in which the lysosome-autophagy pathway can
clear α-syn. Generally, this occurs by ubiquitination of aggregates that
membranes then form around, then they are fused with a lysosome for
degradation (Yamamoto & Simonsen, 2011). Autophagy, more specifically
macroautophagy, is important since it has been shown to clear aggregated α-
syn (Ravikumar et al., 2008), unlike the ubiquitin-proteasome system which
clears soluble protein. In vitro, blocking autophagy results in accumulation of
α-syn (Lee et al., 2004), and α-syn itself has been shown to interfere with
macroautophagy, causing undegraded proteins to buildup (Winslow et al.,
2010).
These two systems work to clear out proteins from the brain of
mammals and are likely both acting on α-syn and are affected by α-syn, as
well as other aggregating proteins in neurodegenerative diseases. Research
continues to fully understand their role in Parkinson’s disease and other
synucleinopathies, and in general their contribution to disease.
2.2.6 ALPHA-SYNUCLEIN AS A BIOMARKER AND DRUG TARGET
Not only is it difficult to diagnose Parkinson’s disease before the motor
symptoms appear, misdiagnosis between other synucleinopathies mentioned
above is also an issue. Since these disorders all present with α-syn-reactive
Lewy bodies, this makes α-syn an attractive candidate for a biomarker.
However, it should be noted that Lewy pathology has also been observed in
asymptomatic human brains post mortem (Klos et al., 2006).
In diagnosing Parkinson’s disease several avenues have been tried to
correlate disease with α-syn presence. Biopsies of the salivary gland have
shown promise: one study showed that staining the submandibular gland for
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α-syn resulted in Lewy body detection in 100% of Parkinson’s patients, and
none of the controls (Del Tredici et al., 2010). Additionally, in colon biopsies
of Parkinson’s disease patients, 72% were positive for Lewy bodies, and no
controls (Lebouvier et al., 2010). Though these biopsy studies are useful, this
is a much more invasive procedure and therefore looking at bodily fluids has
become important in the field. Cerebrospinal fluid (CSF) samples have been
used with mostly positive results, however this is also invasive. Though it has
shown high specificity and sensitivity for Parkinson’s disease patients (Hong
et al., 2010), and interestingly oligomeric (Tokuda et al., 2010) and pS129
(Wang et al., 2012) α-syn were increased in samples from patients. Detection
in blood plasma has also been explored, however this has produced
confounding results due to α-syn’s presence in red blood cells (Barbour et al.,
2008) as well as plasma (El-Agnaf et al., 2003). Though one study found that
quantified α-syn not only showed similar specificity and sensitivity to CSF
samples, but was also correlated with disease severity (Shi et al., 2014), and a
small study showed that pS129 α-syn was higher in Parkinson’s disease
patients than in controls (Foulds et al., 2011). Currently, using blood and
salivary samples are being explored, but larger studies are still needed.
Since α-syn has been shown to be differentially present in Parkinson’s
patients compared to healthy controls, naturally therapy targeting α-syn has
become important. A study screening different compounds for their ability to
reduce SNCA gene expression found that a β2-adrenergic receptor agonist
was able to reduce expression without causing cell death, and interestingly,
that β2 agonists were associated with a decreased risk of Parkinson’s disease
and antagonists with an increased risk (Mittal et al., 2017). This is an
interesting prospect since these drugs already have a wealth of research, are
approved for use in other conditions, and readily cross the blood-brain
barrier. Another route is to target the α-syn protein itself: an immunotherapy
vaccine is being developed (Affiris, 2018), as well as antibodies against α-syn
(Schenk et al., 2017), both of these approaches have reached the clinical trial
stage and have been reported to be safe, but their efficacy in reducing α-syn
levels and their effect on disease outcome remains to be seen. However,
outcomes of a recent trial in Alzheimer’s disease showed no effects on
cognitive outcomes in one study with a monoclonal antibody against amyloid-
β (Salloway et al., 2014) and in another there were no significant differences
between placebo and the antibody treatment on free amyloid-β load (Siemers
et al., 2016). And in fact – the latter drug increased the amyloid-β species,
Aβ1-42, that has been found to be neurotoxic (Gold, 2017). Additionally,
techniques to enhance autophagy pathways to increase α-syn clearance are
being explored (Brundin et al., 2017).
Clearly, researchers and clinicians must continue to search for more
accurate diagnostic measures to diagnose Parkinson’s disease earlier, and
therefore have a higher chance of a successful disease-modifying therapy
while more of the dopamine neurons are still alive. Additionally, therapies
targeting α-syn as the main neuropathological protein in the disease are
potentially promising, however, it is still not fully understood how α-syn
affects disease progression and outcome, making animal models necessary to
not only test new therapeutics, but also model Parkinson’s disease aetiology
and development.
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2.3 ANIMAL MODELS OF PARKINSON’S DISEASE
Generally, animals do not develop Parkinson’s disease as far as we
understand it, though there is a syndrome observed in canines that is similar
to dopamine deficiency and Parkinson’s in humans (Bruyette et al., 1995).
However, the ability to induce Parkinson’s disease-like symptoms and
pathology in animals is still currently a necessity in research. There are a
variety of in vivo models for Parkinson’s disease, in organisms ranging from
yeast to non-human primates. Over the last several decades, these animal
models have developed from more basic toxin models where the main feature
is destruction of the dopaminergic system, to more complex models that
incorporate different facets of the disease such as genetic and α-syn
components (Koprich et al., 2017). Though non-vertebrate Parkinson’s
models are used, rodents and non-human primates tend to be the focus for
two reasons: their physiology is closer to human than non-vertebrates and
preclinical studies in one or more of these species for a new drug are always
necessary before human testing. Currently, there is not one accepted, perfect,
or all-encompassing model for Parkinson’s disease research, and each may be
utilized for its different advantages in modeling the disease.
2.3.1 TOXIN MODELS
A toxin model of Parkinson’s disease involves the administration of a
substance to the animal that will mainly degenerate the nigrostriatal
dopamine system. This loss of dopamine can be unilateral or bilateral and the
degree of loss is often assessed through motor behaviour tests, though more
recently non-motor behaviour is also measured. Generally speaking, these
models do not have obvious α-syn accumulation/Lewy pathology. Their
advantage comes from their quick onset and specific destruction of the
nigrostriatal dopamine system, which can be evaluated post mortem by
markers for dopamine and its related metabolites.
In the early 1980s, MPTP (1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine), mixed with MPPP (1-methyl-4-phenyl-4-
propionoxypiperidine), an analgesic, was sold as a new, synthetic heroin to
drug users and several people who injected it developed immediate onset
parkinsonism that was responsive to dopamine-replacing drugs (Langston et
al., 1983). It was not known at the time since the compound had not been
tested in animals, but it was soon discovered that MPTP is the precursor of
MPP+ (1-methyl-4-phenylpyridinium), which causes specific nigrostriatal
dopamine neuron death (Burns et al., 1983) by a DAT-mediated entry that
then inhibits mitochondrial complex I in these cells (Javitch et al., 1985).
MPTP is now used as a tool to study Parkinson’s disease in animals. A strong
advantage of this model is that it produces very similar dopamine neuron loss
to that observed in Parkinson’s disease (Langston et al., 1983), including
selectively destroying the substantia nigra dopamine neurons, with less effect
on the VTA dopamine neurons, as well as dopamine terminal loss primarily in
the putamen (Snow et al., 2000). The MPTP model is used in mice and
primates, however not in rats since interestingly they were found to be
resistant to the toxin (Chiueh et al., 1984). Also, since MPTP readily crosses
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the blood-brain barrier it can be more easily administered to animals by using
intraperitoneal injections (Jackson-Lewis & Przedborski, 2007), and these
injections cause a bilateral lesion. The main behavioural outcomes are
reduced locomotor behaviour in mice (Jackson-Lewis & Przedborski, 2007),
and can also result in more typical motor symptoms of Parkinson’s disease in
monkeys (Bezard et al., 1997). Non-motor symptoms in non-human primates
have also been measured (Schneider & Kovelowski, 1990). However, this
model generally does not result in any Lewy pathology in animals (Shimoji et
al., 2005; Halliday et al., 2009), though there are reports of it in monkeys
(Kowall et al., 2000). In general, the MPTP model has been used more
extensively in non-human primates to model Parkinson’s disease, and its
ability to cross the blood-brain barrier, as well as its similar effect to human
Parkinson’s patients on the dopaminergic neurons of the nigrostriatal system,
make it a useful tool.
Another commonly used toxin model is 6-hydroxydopamine (6-
OHDA). 6-OHDA is specific to catecholamine neurons, entering the cell
through the DAT or noradrenaline transporter, where it forms reactive
oxygen species independently, and also by inhibiting mitochondrial
respiratory chain complexes I and IV (Evilsizor et al., 2015). Unlike MPTP, 6-
OHDA does not cross the blood-brain barrier and therefore must be
administered directly to the brain using stereotaxic injection (Ungerstedt,
1968). Usually the striatum, substantia nigra, or medial forebrain bundle are
used to degenerate the nigrostriatal system (Deumens et al., 2002), and the
severity of degeneration depends on the injection location (Jeon et al., 1995;
Yuan et al., 2005). Similarly to MPTP, it selectively destroys the nigrostriatal
dopamine system, with less effect on the VTA (Healy-Stoffel et al., 2014). It is
administered unilaterally since bilateral injections show a high mortality rate
and severe behavioural deficits in animals (Ferro et al., 2005). 6-OHDA can
be used to cause a fairly consistent lesion in rats, though dose and
number/location of brain sites may affect the outcome (Penttinen et al.,
2016). It has been successfully used in mice, but a higher variation between
animals is observed (Iancu et al., 2005). The main behavioural evaluation is
also performed by motor tests, typically amphetamine- or apomorphine-
induced rotations (Ungerstedt, 1971). Additionally, non-drug behaviour such
as cylinder test is used (Schallert et al., 2000). These tests can be used since
the unilateral lesion causes dopamine neuron cell death on one side of the
brain. Assessing the degree of the lesion, and the ability of a therapy to
restore dopamine neurons, is often done by measuring the behavioural
outcome on these tests. Typical neuropathology outcome measures are
immunostaining for markers of dopamine neurons such as TH and DAT and
measurement of dopamine content. However, there is also no evidence of
Lewy pathology after 6-OHDA administration. The 6-OHDA model has
mostly been used in rats to affect the nigrostriatal dopamine system and
results in a clear motor phenotype. In the past, current dopamine
replacement therapeutics have been tested in this model and successfully
made it to the clinic (Griebel et al., 2000), giving it some validity as a model
of Parkinson’s disease. Again, as with MPTP, its fast onset and destruction of
the nigrostriatal system make it a model that is still used for Parkinson’s
disease.
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There has been research that Parkinson’s disease may be caused by
environmental toxins (Goldman, 2014), although this is not conclusive, and
may not be true for all patients. Rotenone and paraquat have both been used
to make Parkinson’s toxin models, which are mostly used as a pesticide and
herbicide, respectively. These toxins reproduce the dopamine neuron
degeneration and motor symptoms similar to MPTP and 6-OHDA in animals
(Brooks et al., 1999; Betarbet et al., 2000), although for paraquat it may not
be as specific to the dopamine system (Miller, 2007). Additionally,
administration of rotenone has been shown to cause high mortality and
difficulties in reproducibility (Fleming et al., 2004). The advantage of these
toxins however is that they are able to induce Lewy pathology in dopamine
neurons (Manning-Bog et al., 2002; Sherer et al., 2003).
Though there are several other exogenous toxins that can be
administered to the animal brain to cause destruction of the dopamine
system, of some interest are those that affect the ubiquitin-proteasome
system. As discussed above, essentially, the ubiquitin-proteasome system
clears away or degrades unneeded proteins in the cell, therefore it has become
important in Parkinson’s disease in relation to α-syn, and some genetic
mutations of the disease have been linked to dysfunction in the system
(Olanow & McNaught, 2006). One way to affect this is by administration of
lactacystin, a proteasomal inhibitor. Lactacystin has been shown to cause
dopamine neuron degeneration in rodents after stereotaxic injection to the
substantia nigra, including some deficits in motor behaviour (McNaught et
al., 2002a; Savolainen et al., 2017) (publication V). Importantly, lactacystin
administration has also resulted in buildup of α-syn. This gives the model an
advantage over MPTP and 6-OHDA as it sits between a toxin and an α-syn-
based model. However, since this buildup of protein is due to a general
dysfunction in the proteasome, it is not necessarily specific to α-syn, nor is it
specific to dopamine neurons, which gives the model a disadvantage over
models that specifically use or target α-syn and the dopaminergic system.
Toxin models reproduce the nigrostriatal dopamine system loss seen
in Parkinson’s disease; this happens fairly quickly, making it a less time-
consuming method for researchers and a useful way to test dopamine-
modifying therapies. However, since they mostly lack α-syn pathology this
gives them a disadvantage in that they do not consistently recapitulate this
hallmark of Parkinson’s disease.
2.3.2 GENETIC MODELS
Animal models for the PARK mutations mentioned above have been
made in order to recapitulate the genetic forms of the disease. With mice
being the model organism of choice for genetic models, these are often in
mice. Transgenic overexpression of human wild-type α-syn is perhaps the
most obvious of these models. Several lines of mice have been bred using
different promotors to drive the transgene as well as using mutant forms of α-
syn. For wild-type overexpression, there have been reports of some motor
impairment, loss of TH and dopamine, and also accumulation of α-syn
(Masliah et al., 2000; Richfield et al., 2002), however these models do not
recapitulate the loss of nigrostriatal dopamine neurons. As for the mutated α-
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syn transgenic mice, the A30P and A53T are the most commonly used. Both
mutations have shown behavioural deficits, decreased levels of dopamine in
the striatum, α-syn accumulation, but again no significant neuron loss in the
substantia nigra (Gomez-Isla et al., 2003; Ikeda et al., 2009; Oaks et al.,
2013). Although this is also variable, since some studies have shown nigral
TH+ cell loss without inclusions (Thiruchelvam et al., 2004), and vice versa
(Lee et al., 2002). And in the former study, there was only a small difference
in TH+ cells that only appeared at 20 months of age compared to wild-type
littermates. In general, the outcome seems to depend mostly on which
promoter is used and where the gene integrates, making it difficult to
compare one mouse line to another (Blesa & Przedborski, 2014).
The other PARK genetic models: LRRK2 (overexpression) (Ramonet et
al., 2011), Parkin (KO) (Itier et al., 2003), PINK1 (KO) (Kitada et al., 2007),
DJ-1 (KO) (Goldberg et al., 2005), and ATP13A2 (KO) (Schultheis et al.,
2013), produce some age-dependent motor impairments, and mild dopamine
deficits, though they often do not have α-syn inclusions or strong nigrostriatal
loss. In general, there are a number of genetic mutations used for Parkinson’s
disease animal models, and they may give some hints about disease aetiology,
however often their lack of clear nigrostriatal degeneration and α-syn-positive
Lewy pathology still limits their use.
2.3.3 ALPHA-SYNUCLEIN VIRAL OVEREXPRESSION MODELS
Overexpressing α-syn directly at the substantia nigra using stereotaxic
injections of a virus carrying human α-syn transgene (wild-type or mutant
forms) has become a popular animal model for Parkinson’s disease. Viral
overexpression via lentivirus or AAV vectors are the most often used in order
to recapitulate the widespread α-syn pathology in the substantia nigra as well
as degenerate the nigrostriatal dopamine system.
Lentiviruses are retroviruses (such as HIV) that are made replication-
deficient; the vectors are used to transduce non-dividing cells, making them
useful for neurons (Kay et al., 2001). Lentiviral-mediated α-syn
overexpression using both the human wild-type and mutant forms, as well as
rat α-syn have been studied for their ability to model Parkinson’s disease in
rodents. In rats, both human wild-type and two missense mutations (A30P,
A53T) of α-syn via lentiviral overexpression injected above the substantia
nigra led to TH loss in the nigrostriatal areas, the striatum and substantia
nigra, as well as α-syn-positive inclusions in the surviving substantia nigra
neurons (Lo Bianco et al., 2002). Interestingly, overexpression of rat α-syn
also resulted in inclusions but did not show profound cell loss. A study in
non-transgenic mice with lentivirus carrying the A30P or wild-type human α-
syn, where the animals were followed for one year, showed similar results
when injected to the striatum, substantia nigra, and amygdala (Lauwers et al.,
2003). Overexpression in these areas led to Lewy pathology in cell bodies,
neurites, and the cytoplasm, also in cells other than dopamine neurons. There
was a small loss of TH+ cells in the substantia nigra at 10-12 months post-
injection. In general, lentiviruses overexpressing human α-syn appear to be
effective in disease modelling, however, simultaneously performed studies
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with AAV-α-syn showed higher transduction of TH+ cells, and that may be
one reason why the model has fallen out of favour (Kirik & Bjorklund, 2003).
Using AAV to overexpress specific genes has been used in Parkinson’s
disease modeling as well as in treatment (Domanskyi et al., 2015). Due to its
ability to safely and efficiently transduce cells long-term (Kaplitt et al., 1994)
it has been widely used in animal and human brains (Wu et al., 2006). AAV is
a non-replicating virus that often does not result in immune reactions in
human cells and is not associated with disease in primates (Chirmule et al.,
1999). AAVs are currently being utilized in several clinical trials, including in
Parkinson’s disease as discussed above. Additionally, its use in Parkinson’s
disease modeling has been fairly extensive over the last several years.
Overexpression of human α-syn using AAV encoding SNCA has been used in
rodents and non-human primates, where both the wild-type and mutant
forms are utilized. The most common method is to unilaterally inject AAV-α-
syn above the substantia nigra where it transduces dopamine neurons of the
nigrostriatal tract. This causes a progressive loss of TH and results in the
presence of α-syn, and this onset of loss is generally slower and less severe
than the toxin 6-OHDA (Decressac et al., 2012a). The loss is accompanied by
unilateral motor deficits. This gives the model good validity in modeling
Parkinson’s, where the sporadic disease has a mostly slow onset and the
presence of α-syn. However, these studies use different AAV serotypes and
promoters, which may affect cell specificity and degree of transduction
(Tenenbaum et al., 2004). Also, wild-type versus mutant α-syn, end points,
and outcome measures are often different (reviewed in (Albert et al., 2017),
publication I, and summarized in Table 3). These experiments result in TH
loss in the substantia nigra pars compacta across species, however it is not
always clear if striatal TH, dopamine levels, or motor behaviour are affected.
Table 3. Summary of AAV-α-syn studies in wild-type rodents that use human forms of α-syn for
overexpression to the substantia nigra and measure the typical outcomes for the nigrostriatal
system and related behaviour compared to a control. Modified from (Albert et al., 2017).
Strain Insert Serotype/
Promoter
Duration STR
TH
fibre
dens.
SNpc
TH+
cells
STR
DA
Behav. Ref.
C57BL/
6 mice
WT
A53T
AAV2/7 /
CMV (w/
WPRE)
8 weeks N/A ↓ N/A WT:
motor
deficits
(Oliveras-
Salva et
al., 2013)
C57BL/
6 mice
WT rAAV /
CMV (w/
WPRE,
IRES)
24 weeks N/A ↓ N/A N/A (St Martin
et al.,
2007)
C57BL/
6 mice
A53T AAV1/2 /
CBA (w/
CMV,
WPRE,
bGH-
polyA)
10 weeks ↓ ↓ ↓ Motor
deficits
(Ip et al.,
2017)
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C57BL/
6 mice
A53T rAAV (w/
WPRE)
7 weeks ↔ ↔ ↔ N/A (Dong et
al., 2002)
C57BL/
6 mice
WT AAV2 /
CBA (w/
WPRE,
IRES)
24 weeks N/A ↓ N/A N/A (Thome et
al., 2015)
C57BL/
6 mice
WT rAAV2/1 12 weeks ↓ ↓ ↓ Motor
deficits
(Song et
al., 2015)
C57BL/
6 mice
WT AAV2 /
CBA
8 weeks ↓ ↔ ↓ ↓ (Svarcbah
s et al.,
2016)
SD rats WT rAAV /
CBA (w/
CMV
elements)
27 weeks ↓ ↓ ↓ No
motor
deficits*
(Kirik et
al., 2002)
SD rats WT AAV6 /
CBA (w/
and w/out
WPRE)
16 weeks ↓
WPRE
↓
WPRE
↓
WPRE
Motor
deficits
w/
WPRE
(Decressa
c et al.,
2012b)
SD rats WT AAV2/5 /
CBA/
CMV
8 weeks N/A ↓ N/A Some
motor
and
non-
motor
deficits
(Gombash
et al.,
2013)
Fisher
344
rats
WT AAV9 /
CBA
12 weeks N/A ↓ N/A Motor
deficits
(Shahadu
zzaman et
al., 2015)
SD rats WT rAAV /
CMV
13 weeks N/A ↓ ↔ No
motor
deficits
(Yamada
et al.,
2004)
SD rats WT
S129A
S129D
AAV2/5 /
CMV/CBA
15 weeks ↓ ↓ N/A Some
motor
deficit
(Febbraro
et al.,
2013)
SD rats A53T AAV1/2 /
CBA/CMV
(w/
WPRE,
bGH-
polyA)
6 weeks ↓ ↓ ↓ Some
motor
deficit
(Koprich
et al.,
2011)
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SD rats WT
A30P
AAV2/6 /
CMV (w/
WPRE)
16 weeks ↓ ↓ ↓ Some
motor
deficit
(Gaugler
et al.,
2012)
Wistar
rats
WT
A53T
AAV2/7 /
CMV/
synapsin
29 days N/A A53T:
↓
A53T:
↓
A53T:
Some
motor
deficit
(Van der
Perren et
al., 2015)
SD rats WT AAV5 /
human U6
8 weeks N/A ↓ ↓ No
motor
deficit
(Gully et
al., 2016)
SD rats WT AAV5 /
CMV
8 weeks ↓ ↓ N/A N/A (Landeck
et al.,
2016)
SD rats WT AAV2/6 /
CMV/
synapsin
(w/
WPRE)
5 weeks ↓ ↓ ↓ Motor
deficits
(Decressa
c et al.,
2013)
SD rats A53T AAV1/2 /
CBA/CMV
(w/
WPRE,
bGH-
polyA)
6 weeks ↓ ↓ ↓ Motor
deficits
(He et al.,
2016)
SD rats WT AAV6 /
synapsin
(w/
WPRE)
8 weeks ↓ ↓ N/A Some
motor
and
non-
motor
deficits
(Caudal et
al., 2015)
SD rats A53T AAV2 /
CMV (w/
CBA,
WPRE)
8 weeks ↓ N/A N/A N/A (Arawaka
et al.,
2014)
Wistar
rats
WT
A53T
rAAV /
CBA/CMV
(w/
WPRE)
12 weeks ↓ no
quant.
↓ no
quant.
N/A Motor
deficit
(Lu et al.,
2015)
SD rats WT
S129A
S129D
AAV2/8 /
CBA (w/
WPRE)
6 weeks ↔ ↓ ↔ N/A (McFarlan
d et al.,
2009)
Fisher
344
rats
WT AAV9 /
CBA/CMV
(WPRE,
bGH-
polyA)
16 weeks N/A ↓ N/A N/A (Pabon et
al., 2012)
Review of the Literature
27
SD rats WT AAV2/5 /
CMV
18 weeks ↔ ↔ N/A N/A (Moloney
et al.,
2014)
SD rats WT AAV2/5 /
pDG-5
promoter
24 weeks ↓ ↓ N/A Motor
deficits
(Mulcahy
et al.,
2012)
SD rats WT AAV2/6 /
synapsin
(w/
WPRE)
bilateral
injections
40 weeks ↔ ↓ N/A Motor
deficits
(Crowley
et al.,
2018)
Rats WT
S129A
S129D
rAAV /
CBA (w/
CMV
elements)
26 weeks N/A ↓ ↓WT
S129A
N/A (Gorbatyu
k et al.,
2008)
Rats WT AAV5 8 weeks N/A ↓ ↓ Motor
deficits
(Gorbatyu
k et al.,
2012)
SD rats WT rAAV2/5 /
CBA
15 weeks N/A ↓ N/A N/A (Sanchez-
Guajardo
et al.,
2010)
SD rats A53T AAV2 /
synapsin
24 weeks N/A ↓ ↓ N/A (Chung et
al., 2009)
SD rats WT rAAV2/5 /
CBA/CMV
(w/
WPRE)
13 weeks N/A ↔ N/A Motor
deficits
(Andersen
et al.,
2018)
N/A refers to the fact that an outcome measure was not included in the article; ↓ A decrease in the
parameter was shown; ↔ No change in the parameter was shown; * With TH enzyme blocker on
stepping test; ‘Rats’ indicates no strain specified in article; STR: striatum; SNpc: substantia nigra
pars compacta; SD: Sprague Dawley; TH: tyrosine hydroxylase; DA: dopamine; CBA: chicken β-
actin; CMV: cytomegalovirus; WT: wild-type; WPRE: woodchuck hepatitis virus posttranscriptional
regulatory element; IRES: internal ribosome entry site; bGH-polyA: bovine growth hormone
polyadenylation sequence.
The AAV overexpression model has been shown to be successful in its
recapitulation of α-syn expression in the nigrostriatal tract accompanied by
TH loss and motor behaviour deficits, but there are also serious flaws to it. A
recent study concluded that using AAV encoding human α-syn in rats is not
an ideal model for sporadic Parkinson’s disease (Su et al., 2017). Since in the
AAV model, α-syn mRNA is constitutively increased (Decressac et al., 2012b),
however in Parkinson’s disease SNCA mRNA is actually decreased (Kingsbury
et al., 2004). The above-mentioned study confirmed that SNCA is
upregulated in the AAV-α-syn model in rats (Su et al., 2017). Additionally,
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there have been concerns with controls (publication I). It has been shown that
when AAV-eGFP is expressed at the same titer as AAV-α-syn, it can also cause
loss of TH (Landeck et al., 2016; Andersen et al., 2018), and that AAV itself
may downregulate TH (publication II).
While the face validity of AAV-α-syn is sound since it appears to be
imitating the disease well, it is pertinent to ask whether this is the most
accurate model of sporadic Parkinson’s disease – in other words does it have
construct validity. The need for an appropriate control and problems with the
model also bring up questions about its usefulness in therapy testing.
2.3.4 PREFORMED ALPHA-SYNUCLEIN FIBRILS MODEL
Overexpression of α-syn via viral vector may be useful, however α-syn
is expressed at high levels, transduces the neurons, and causes rapid cell
death due to protein buildup, which does not necessarily mimic sporadic
Parkinson’s disease. Recently, a new model was developed and has become
popular over the last few years. The preformed α-syn fibrils (PFF) model of
Parkinson’s disease mimics the way α-syn acts like a prion protein as well as
the formation of Lewy bodies: when it is injected stereotaxically or applied to
culture it spreads from one neuron to another by recruiting endogenous α-syn
that builds up in the cell body and neurites.
As mentioned above, the fibrillar form of α-syn is considered an
insoluble form of the protein that relates to aggregation and formation of
Lewy bodies. Since there is clear Lewy pathology in human brains with
Parkinson’s disease, in vitro and in vivo models using fibrils to mimic this
were developed. Luk and others (2009) demonstrated that purified human
wild-type α-syn fibrils will seed endogenous α-syn and form Lewy body-like
inclusions that contain ubiquitin, are insoluble, and are pS129-positive (Luk
et al., 2009), thus making them similar to Lewy bodies in human disease. A
further study using primary neuron culture demonstrated that the Lewy
bodies formed by the fibrils propagate in the cells and consequently lead to
neuronal dysfunction and death (Volpicelli-Daley et al., 2011).
With their ability to form Lewy pathology and cause cell death in vitro,
the PFFs have now been used extensively in rodents. From a later paper by
Luk and others came one of the first studies in wild-type mice (Luk et al.,
2012). The authors demonstrated that injection of mouse PFFs into the
striatum of the mice resulted in clear α-syn-positive inclusions throughout
the ipsilateral striatum, cortex, olfactory bulb, amygdala, and importantly the
substantia nigra pars compacta. This was accompanied by reduced dopamine
content at three months post-injection, TH loss in the striatum and
substantia nigra at six months, as well as behavioural deficits. Interestingly,
these deficits appear only after three to six months after injection,
demonstrating that this is a much slower process than either viral vectors or
toxin models. Although, perhaps unlike in Parkinson’s disease in humans, α-
syn is seeded and spread much more quickly in the model in mice (Okuzumi
et al., 2018). Other groups have shown similar results using PFFs in rodents
and primates. In rodents, PFFs have been injected to several different areas.
Injection of mouse PFFs to the striatum of both mice and rats results in
robust pS129 pathology in the cortex, amygdala, and substantia nigra pars
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compacta (Abdelmotilib et al., 2017). In both species the amount of α-syn
pathology correlated to loss of TH+ cells in the substantia nigra pars
compacta. Interestingly, injection of pS129 PFFs into the mouse striatum
resulted in TH cell loss in the substantia nigra pars compacta and some motor
impairment already at two months, compared to the wild-type PFFs
(Karampetsou et al., 2017), but at the moment this has not been explored
further. In a study that also injected PFFs into the striatum of mice, the
authors showed that there was dendritic spine loss in the cortex
(Blumenstock et al., 2017). Although the same was not the case when PFFs
were injected into the hippocampus of mice, where pS129-positive inclusions
formed in hippocampal neuronal connections but there was no cell loss or
memory deficits (Nouraei et al., 2018). Another study where PFFs were
injected into the olfactory bulb in order to create a prodromal model of
Parkinson’s disease showed inclusions in connecting brain areas and that
there were deficits in the olfactory system measured through behavioural
tests; this occurred progressively over the 12 months of the study (Rey et al.,
2016), but leveled off, in other words there was no further spreading or
increase in severity of pathology, at 23 months (Rey et al., 2018). Other than
the olfactory bulb, it is thought that α-syn pathology may spread from the
gastrointestinal tract to the central nervous system via the vagus nerve, thus
also explaining the prodromal gastrointestinal symptoms observed in
Parkinson’s disease. A study in mice applied PFFs to the gastric wall and
found phosphorylated α-syn/Lewy body pathology in the dorsal nucleus of
the vagus nerve, however this did not propagate further and was not specific
to any particular cell type, as would be hypothesized with Braak staging
pathology (Uemura et al., 2018). However, a similar study in rats and non-
human primates found gastrointestinal deficits in the rat after PFFs were
injected to the descending colon, as well as Lewy body-like inclusions in the
enteric nervous system and brain stem (Manfredsson et al., 2018). For the
non-human primate, injection of PFFs into the colon and stomach also
resulted in enteric nervous system pathology. When rats are used for PFF
studies, similar results have been obtained as for mice with striatal injections
of mouse PFFs. Lewy body-like inclusions were found in cortex, amygdala,
and substantia nigra pars compacta, and this resulted in degeneration in the
dopamine system at six months post-injection, however no motor deficits
were observed (Paumier et al., 2015). Another study in rats had similar
results, and also demonstrated microglial activation, related to an
inflammatory reaction in the brain (Duffy et al., 2018). Additionally, injection
of mouse PFFs to the marmoset putamen resulted in pS129-positive
inclusions and loss of TH+ cells in the substantia nigra pars compacta on the
ipsilateral side already at three months after injection (Shimozawa et al.,
2017).
The PFF model appears to be relatively successful across species and
consistently results in seeding of endogenous α-syn in the connected areas,
although cell death and behavioural deficits are not always present. This may
depend on the species of purified α-syn used (ex. human versus mouse), since
it was shown that seeding may be more efficient in the matching species, in
other words α-syn that was more homologous to mouse α-syn was more
effective in mice (Luk et al., 2016). Additionally, the lack of severe
nigrostriatal dopamine degeneration has been overcome by simultaneously
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overexpressing α-syn via AAV with PFF injection (Thakur et al., 2017). In
general, as with any animal model that adds exogenous material, severity may
depend on how much is added and the duration of the experiment.
2.4 CEREBRAL DOPAMINE NEUROTROPHIC FACTOR
(CDNF)
Cerebral dopamine neurotrophic factor (CDNF) was first characterized
in 2007 (Lindholm et al., 2007). Mature human CDNF is 161 amino acids and
is highly conserved in vertebrates. Although its mechanism of action is
dissimilar to other neurotrophic factors, it has been shown to be effective in
animal models of disease, most importantly Parkinson’s.
2.4.1 CDNF AND RELATED FACTOR MANF
Human mesencephalic astrocyte-derived neurotrophic factor (MANF)
shares 59% amino acid identity with human CDNF (Lindholm et al., 2007;
Lindholm & Saarma, 2010), and these two factors form an evolutionarily
conserved group of proteins. Their similar structure may be related to both
lipid or membrane binding, as well as regulation of ER stress (Parkash et al.,
2009), which gives hints about how these proteins function. Specifically, the
N-terminal domain is a saposin-like domain which is known to interact with
lipids, and the C-terminal with its single cysteine bridge is similar to other
proteins that function at the ER (Ellgaard & Ruddock, 2005). Furthermore, at
the end of the proteins’ C-terminus are a KTEL (CDNF) and RTDL (MANF)
sequence which are known as ER retention signals. And in fact, in vitro
deletion of the RTDL sequence in MANF prevented its localization to the ER
(Glembotski et al., 2012; Matlik et al., 2015), and in another study increases
its secretion as well (Henderson et al., 2013). Interestingly, in the same study,
the RTDL sequence was not required for in vivo protection of neurons but
seemed to be dependent on the CXXC part of the C-terminal domain. It has
also been demonstrated that CDNF may function in a similar way with its
KTEL sequence (Norisada et al., 2016). MANF expression has been shown to
increase after thapsigargin, tunicamycin, and lactacystin treatment of cells
(Apostolou et al., 2008), compounds known to activate the unfolded protein
response (UPR). Additionally, its cellular secretion in response to
thapsigargin occurs only when ER calcium is depleted (Henderson et al.,
2014).
Both MANF and CDNF (human or rodent) are expressed in the central
and peripheral nervous systems of adults. Interestingly, MANF has been
detected in human blood serum at a level of 7 ng/mL (Galli et al., 2016).
While levels of CDNF mRNA and protein have been shown to be generally
lower than MANF, they show a partially overlapping expression pattern
(Lindholm et al., 2007). CDNF transcript has been shown to be present in the
human brain, and in adult mice using a CDNF-specific antibody it was
detected in the cerebral cortex, hippocampus, locus coeruleus, and the
Purkinje cells of the cerebellum. In the periphery, human CDNF is at its
highest levels in skeletal muscle, heart, lung, and testis compared to other
tissues.
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A model of MANF KO has been characterized and it was found that
these mice develop type 1 diabetes due to loss of pancreatic β cells (Lindahl et
al., 2014), which was caused by increased and constitutive activation of the
UPR pathway (Danilova et al., 2019). However, characterization of CDNF KO
mice has shown that they are viable and fertile, although they have some
defects in the enteric and midbrain dopamine neurons (Lindahl et al.,
manuscript).
MANF, and CDNF in particular, are unlike other classical neurotrophic
factors such as GDNF. GDNF, for example, will, upon secretion, bind to its
co-receptor GFRα1 to activate transmembrane tyrosine kinase receptor Ret
and promote neuronal growth and survival (Airaksinen & Saarma, 2002). By
contrast, CDNF’s mode of action is still unclear. Both factors are functioning
intracellularly and CDNF seems not to be secreted from neurons, even after
robust overexpression via lentivirus (Matlik, 2017). Their N-terminal and C-
terminal sequences connote dual modes of action: the N-terminal motif
seems to be important for lipid binding and the C-terminus exerts effects for
localization at the ER. Though similarly to classical neurotrophic factors,
CDNF has been shown to protect neurons in vitro (Arancibia et al., 2018) and
in vivo when a stressor or lesion is applied. Additionally, these proteins are
likely functioning differently when given exogenously, as opposed to their
endogenous actions. There is evidence of this from when CDNF was
exogenously applied by stereotaxic injection to the brain and it was shown to
be efficiently taken up by the neurons (Matlik et al., 2017). However, further
research is needed to fully comprehend how CDNF, and MANF, are
functioning in the central nervous system.
2.4.2 CDNF IN PARKINSON’S DISEASE
When CDNF was first characterized, it was shown to be
neuroprotective in the 6-OHDA model of Parkinson’s disease (Lindholm et
al., 2007). When CDNF was injected stereotaxically to the striatum four
weeks after 6-OHDA in rats, it resulted in significantly fewer amphetamine-
induced ipsilateral rotations and protected the TH+ cells in the substantia
nigra pars compacta compared to vehicle. Since then, it has been shown to
not only be protective in Parkinson’s disease models, but also in other rodent
disease models. CDNF enhanced long-term memory in wild-type mice and in
a transgenic model of Alzheimer’s disease, however it did not increase
neurogenesis or decrease amyloid-β accumulation (Kemppainen et al., 2015).
It was also shown to be anti-inflammatory when given via bone marrow-
derived mesenchymal stem cells that overexpress CDNF to a rat model of
spinal cord injury where it reduced expression of cytokines, protected the
cells from injury, and resulted in improved locomotor behaviour (Zhao et al.,
2016).
Since the initial study showed CDNF to be neuroprotective in a 6-
OHDA model, it has been studied the most for Parkinson’s disease. In a
mouse model using MPTP, CDNF was given bilaterally to the striatum before
or after MPTP which resulted in improved locomotor activity, as well as
protection of TH fibres in the striatum and TH+ cells in the substantia nigra
pars compacta (Airavaara et al., 2012). In another 6-OHDA experiment,
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CDNF was given continuously over a two-week period to the striatum after
the toxin injection, which also resulted in recovery on amphetamine-induced
rotations, as well as protecting against the loss of TH fibres in the striatum
and TH+ cells in the substantia nigra pars compacta (Voutilainen et al.,
2011). Thus, CDNF seems to be protective over long administration periods,
as opposed to GDNF, where sustained overexpression does not necessarily
result in increased improvement over single injection (Penttinen et al.,
2018b). A recent study repeated the experiment similarly to Lindholm et al.
2007, but with a lower dose of CDNF (Voutilainen et al., 2017), however at
the low doses used CDNF did not reach significance compared to vehicle.
Another study administered CDNF to the substantia nigra one week after a 6-
OHDA lesion of the medial forebrain bundle but did not show any positive
effects, however interestingly, when CDNF was given to the substantia nigra
four weeks after the lesion, there was some functional recovery on
apomorphine-induced rotations (Huotarinen et al., 2018). This study also
used CDNF injection to the substantia nigra in combination with deep brain
stimulation of the STN and showed a positive effect on apomorphine-induced
rotations and cylinder test compared to CDNF or stimulation alone. However,
the efficacy of CDNF may depend on lesion size and progression as well as on
the CDNF administration paradigm. Our unpublished results show that there
is a clear functional recovery on amphetamine-induced rotations at eight
weeks when CDNF was given as a single injection to the striatum, substantia
nigra, or both, two weeks after a severe 6-OHDA lesion, but there was no
protection of TH fibres in the striatum or TH+ cells in the substantia nigra at
twelve weeks when the experiment was ended (unpublished results).
Therefore, caution in experimental setup is crucial, and naturally the degree
of the lesion will strongly affect the outcome.
The above studies use the exogenous human CDNF protein alone, but
AAV carrying human CDNF has also been used somewhat successfully in the
6-OHDA model. Rats received AAV2-CDNF two weeks before 6-OHDA and
while this reduced the number of amphetamine-induced rotations, it only
showed some protection of striatal TH fibres and nigral TH+ cells at the
highest titer (Back et al., 2013a). This could be due to the spreading of the
protein in the striatum with AAV: there was very minimal detection of the
protein in the striatum and substantia nigra with immunohistochemistry, but
Voutilainen and others (2011) and Mätlik and others (2017) show that CDNF
protein alone is spreading robustly in the striatum at two to six hours, and
that it is detected in the substantia nigra (Voutilainen et al., 2011; Matlik et
al., 2017). We have also observed similar results with the CDNF protein by
itself after nigral injection (publication IV). However, despite this, another
study has shown significant positive results with AAV2-CDNF (Ren et al.,
2013), and AAV8-CDNF also showed positive effects on TH, but only in a
mild lesion paradigm (Wang et al., 2017). Additionally, a study using
lentiviral CDNF showed less efficacy after striatal injection when given at the
same time as 6-OHDA, but did show some functional effect on behaviour
after nigral injection (Cordero-Llana et al., 2015). However, this study did not
show any CDNF expression data and due to the composition of the expression
vector it is difficult to interpret where it localizes in the brain, and therefore it
may not be optimally exerting its effects. A study using a transiently
transfected CDNF plasmid carried by a neurotensin-polyplex was injected to
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the substantia nigra of rats after a striatal 6-OHDA lesion and resulted in
reduced numbers of activated glial cells in the substantia nigra pars compacta
(Nadella et al., 2014). CDNF has also been tested in monkeys, where it
showed an increase in DAT activity in the striatum after a 6-OHDA lesion
(Garea-Rodriguez et al., 2016). Importantly, it is currently in clinical trials for
Parkinson’s disease in Sweden (Herantis Pharma, 2017b) and Finland
(Herantis Pharma, 2017a). A brief summary of the CDNF animal studies in
Parkinson’s models is shown in Table 4.
Table 4. Summary of studies using CDNF in animal models of Parkinson’s disease toxin models.
Experiment Main result Reference
CDNF protein (10µg)
unilateral injection to STR
of rats
Positive effects on behaviour and TH (Lindholm et al.,
2007)
CDNF protein (10µg)
bilateral injection to STR
of mice
Positive effects on behaviour and TH (Airavaara et al.,
2012)
CDNF protein chronic
infusion to STR of rats
Positive effects on behaviour and TH (Voutilainen et al.,
2011)
CDNF protein (1-5µg)
unilateral injection to STR
of rats
No significant effects on behaviour and TH
compared to vehicle
(Voutilainen et al.,
2017)
CDNF protein (10µg)
unilateral injection to SN
of rats
Positive behaviour effect; no significant effect
on TH compared to vehicle
(Huotarinen et al.,
2018)
AAV2-CDNF unilateral
injection to STR of rats
Positive effects on behaviour and TH (Back et al.,
2013a)
AAV2-CDNF unilateral
injection to STR of rats
Positive effects on behaviour and TH (Ren et al., 2013)
AAV8-CDNF unilateral
injection to STR of rats
Positive effects on behaviour and TH (Wang et al.,
2017)
Lentiviral CDNF
unilaterally to STR or SN
of rats
No significant effects on behaviour or TH
with STR injection; positive effects on
behaviour with SN injection
(Cordero-Llana et
al., 2015)
CDNF plasmid to SN of
rats
Positive effects on inflammatory cells (Nadella et al.,
2014)
CDNF protein chronic
infusion to STR of
monkeys
Increase in DAT activity (Garea-Rodriguez
et al., 2016)
While CDNF has shown clear efficacy in toxin models, we only have
some evidence of how it fares in α-syn-based models (manuscript, publication
III). A published in vitro study showed that application of an excessive
amount of CDNF to neuronal culture treated with a large amount of PFFs one
hour before resulted in protection of the cells (Latge et al., 2015). This is
interesting, and our results give hints towards a direct interaction between
CDNF and α-syn (manuscript, publication III), as well as some positive in
vitro and in vivo effects. However, further experiments are certainly needed
to elucidate the mechanism and understand the full effect of CDNF on α-syn
in Parkinson’s disease models.
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3 AIMS
The overall aim of this thesis was to model α-synuclein-based Parkinson’s
disease in rodents in order to test cerebral dopamine neurotrophic factor
(CDNF) as a therapy. CDNF has been effective in neurotoxin models, and it is
currently in clinical trials for Parkinson’s disease patients. Therefore, it
became pertinent to test it in α-synuclein models.
The specific aims were:
1. Model Parkinson’s disease in rats using adeno-associated virus (AAV)
to overexpress human α-synuclein. AAV-α-synuclein models have been
shown to successfully recapitulate typical features of toxin models:
nigrostriatal neurodegeneration and motor behavioural deficits, but
with the presence of α-synuclein. Therefore, we wanted to validate this
as a model for testing new therapies.
2. Model Parkinson’s disease in rodents using preformed fibrils to seed
endogenous α-synuclein in the brain in order to test CDNF’s effects on
the model. The preformed α-synuclein model has been shown to
recreate the spreading of α-synuclein from cell to cell in vitro and in
vivo, accompanied by deficits in motor behaviour and loss of
nigrostriatal dopamine neurons in mice and rats. It is considered to be
a model of Lewy pathology and progressive spreading of pathogenic α-
synuclein. We therefore set up this model to test CDNF in.
3. Characterize the effects of nigral administration of CDNF in vivo.
CDNF is currently in clinical trials for Parkinson’s disease and the
striatal administration has been characterized, therefore we wanted to
characterize its effects when stereotaxically injected to the substantia
nigra of naïve rats.
4. Model an α-synuclein-based Parkinson’s disease phenotype in mice
using lactacystin. Injecting the proteasomal inhibitor lactacystin to the
substantia nigra of mice has resulted in protein buildup in the
nigrostriatal tract, including α-synuclein, as well as behavioural
deficits and loss of dopamine neurons. We wanted to further
characterize and validate this model as another way of modeling α-
synuclein-related Parkinson’s animal models.
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4 MATERIALS AND METHODS
Table 5. Collection of the main methods used in the studies.
Method Study
Preparation of injection material
6-OHDA preparation II
CDNF preparation III, IV
Iodination of proteins IV
Preformed fibrils preparation III
Viral vector preparation II
Stereotaxic injections II, III, IV, V
Behaviour
Amphetamine-induced rotations II
Coat hanger test III
Cylinder test II, III, V
Locomotor activity V
Rotarod III
Tissue collection and processing II, III, IV, V
Biochemical assays
High-performance liquid chromatography
(HPLC)
II, III, V
Immunohistochemistry II, III, IV, V
Immunofluorescence III, IV, V
Imaging and analysis
Confocal microscopy IV, V
Counting of phosphorylated alpha-synuclein
inclusions
III
Counting of TH+ cells II, V
Optical density measurement II, III, V
4.1 METHODOLOGICAL CONSIDERATIONS
4.1.1 ANIMAL STRAINS
The following strains were used in the experiments:
· C57BL/6JRccHsd mice (male)
· C57Bl/6JRj mice (male)
· C57BL/6JOlaHsd mice (male)
· CDNF KO (male)
· Hsd:HanWistar rats (male)
· Hsd:Sprague Dawley rats (male and female)
It is well-known in the scientific community that strain can potentially
affect the results of animal experiments. Effects can range from very clear,
such as the fact that MPTP, a toxin used to model Parkinson’s disease due to
its mechanism in humans, is most effective in a certain strain of mice (Riachi
& Harik, 1988), to more complex, for example the observations that mouse
strains have varying levels of anxiety and aggression (Parmigiani et al., 1999),
and that behaviour can even be different throughout an animal’s lifespan
(Shoji et al., 2016). Strain needs to be factored into experiment planning, and
can have long reaching effects, particularly when considering inbred strains
as well as their use in breeding genetically modified animals. Though we have
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used genetic models minimally in the current studies, strain is an important
aspect here, particularly in regard to the α-syn models.
While inbred strains of animals are considered to be isogenetic, it is
possible that expression levels of certain proteins may change over time due
to continuous breeding (Davis et al., 2012). This can be particularly
problematic in the long term, resulting in higher variability between animals,
experiments, and labs. Although one could take a more optimistic perspective
and consider that if your model or treatment works from experiment to
experiment, and similarly in another lab, then this would give increased
clinical relevance to it since humans are not all the same genotype. However,
it is nonetheless important to have knowledge of such strain differences. An
important example from the current studies is the C57BL/6JOlaHsd strain of
mice, where it was discovered that these mice carry a mutation for the α-syn
gene (Specht & Schoepfer, 2001). This essentially makes these α-syn KO
animals. As long as researchers are aware of this, these mice can be used as
controls in experiments, as we have done (publication III), but if the
researcher is not aware, this can be a significant waste of time, effort, and
money. This is especially true in general for behavioural neuroscience
experiments, and in this case α-syn-based experiments.
In contrast to measurable changes at the gene level, animal strains may
differ in their behaviour as mentioned above. This is more difficult to quantify
with certainty, and also may change between labs and animal suppliers.
However, in the current studies we found differences in non-drug induced
motor behaviour between rat strains. In publication II we observed
significantly more rearings with the Sprague Dawley rats compared to the
male Wistar rats (publication II, Figure 1d). Therefore, we used this strain for
future studies since with a higher number of rearings per rat we can obtain
more accurate results. This demonstrates that even a supposedly
straightforward factor such as the natural behaviour of a rodent standing on
its hindlegs can be affected by strain.
Another important factor in animal studies is the sex of the animal. Male
mammals are most often used by researchers due to concerns about
hormonal cycles affecting inter-subject differences (Beery & Zucker, 2011).
However, several studies have revealed sex differences in neurodegenerative
diseases (Tierney et al., 2017), and it is therefore important to use both sexes
in studies or to consider that studies in, for example, male rodents, do not
extrapolate to female rodents. Just as we must consider the jump from
rodents to primates to humans in research, we must consider sex differences
as well. In these studies, we have also used mostly male rodents, except in
publication II where we used female Sprague-Dawley rats fairly exclusively,
and this is mentioned. However, any potential sex differences were not
examined. This is something that could be considered in future studies,
particularly since there are reported gender differences between men and
women in Parkinson’s disease, where women had higher striatal dopamine,
lower incidence of the disease, as well as later age of onset than men (Haaxma
et al., 2007), indicating sex as a fairly significant factor.
4.1.2 INTRACRANIAL MICROINJECTIONS
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An aspect of stereotaxic injections that is often not discussed in the
literature is which injection paradigm to use. When considering intracranial
injections of any kind, we tend to focus on the target, but what receives less
attention is the fact that we are placing a needle from the top of the skull deep
into the brain. The needle has the opportunity to wreak havoc in the
surrounding tissue that may cause problems related to unspecific damage of
neurons and arteries, as well as inflammation. Therefore, any way to mitigate,
or at least be aware, of these problems is useful.
While location of the injection is usually an obvious consideration,
needle type, volume, and flow rate are factors that can greatly affect the
outcome of an injection. Extensive testing may be needed to find the optimal
paradigm for the substance you are injecting. For example, needle gauge and
number of injection locations have been shown to affect the outcome in a 6-
OHDA model in rats (Penttinen et al., 2016). A potential confounding factor
here is that wider steel needles may cause more unspecific damage to the
surrounding area of the brain than thinner needles, and in the
aforementioned study it was calculated that the larger needle diameter could
cause a mechanical lesion equal to 5.1% of the total striatal volume. In the
case of publication II, we used glass capillaries to inject the AAVs which have
been shown to cause less mechanical damage than steel needles (Gonzalez-
Perez et al., 2010), and in publication III we used thinner steel 33G needles
for injections to reduce mechanical damage. Concerning flow rate and
number of injection locations, we tested this thoroughly in publication II. We
found that injecting the AAVs to one site above the substantia nigra at a
volume of 4 µl with a flow rate of 0.1 µl/min resulted in widespread
expression of the transgene (publication II, Figure 1a), whereas when we
injected the AAVs to two sites (2 µl/site) and a flow rate of 0.5 µl/min, this
resulted in specific midbrain expression (publication II, Figure 1b-c).
Therefore, it is clear that injection paradigms can affect spread and
expression of the substance of interest, as well as considerations of
mechanical damage that may result in further unspecific destruction in the
brain. These factors need to be considered based on what one aims to achieve.
4.1.3 POSITIVE AND NEGATIVE CONTROLS IN DISEASE MODELING
The impact of having proper positive and negative controls cannot be
overstated. While it is more common in the literature to have both positive
and negative controls in therapeutic drug testing so that it is clear that the
drug of interest is having the desired effect, a proper control to compare in
disease modeling is less discussed.
In this case, disease modeling refers to injecting a protein or substance
of interest in order to recapitulate factors that constitute a neurodegenerative
disease in an animal, thus making an animal model of disease to either
further understand disease aetiology or to test a therapy. In this thesis, we
have used a 6-OHDA toxin model, the lactacystin model, an AAV-α-syn
model, and the α-syn PFF model. In these models, a positive control may be
less necessary since we are trying to characterize the effects of the injection
material in the animals, and therefore there may not be an appropriate
comparison. However, when establishing a new model it may be useful to
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compare the outcome to another similar model that is the current standard in
the field. For example, (Decressac et al., 2012a) showed a side by side
comparison of 6-OHDA versus AAV-α-syn when the latter model was first
becoming established. Using 6-OHDA as a positive control for comparison
allowed the authors to show the differences and potential advantages of AAV-
α-syn over the 6-OHDA toxin. Additionally, we have used 6-OHDA similarly
as a positive control in publication II, where we wanted to show the clear
deficits in cylinder behaviour and how it correlates to loss of striatal TH in the
6-OHDA model, however the same was not the case with AAV-α-syn; there
was essentially no correlation between cylinder behaviour and TH loss in the
striatum in the AAV model (publication II, Figure 2f-g). These comparisons
can be important for other researchers to further understand the model, and
that it may not be working in the same way as already established models for
Parkinson’s disease. This type of comparison to a positive control can save
researchers time and effort in how they measure outcomes.
In disease modeling, negative controls are a necessity. One has to be
sure that their protein or substance of interest is specifically causing the
outcome, or it may not constitute a good disease model. In toxin models such
as 6-OHDA and lactacystin, the negative control is often phosphate buffered
saline (PBS), saline, artificial cerebral spinal fluid (aCSF), or a sham
operation. These can be useful, with the idea being that they are not causing
any damage on their own and also controlling for the injection. However, a
different control for 6-OHDA could be a substance that would cause less
specific neuronal damage, instead of specifically degenerating the
dopaminergic system so it would be clear that the outcome measures in the
model are useful and correct. Additionally, in the case of 6-OHDA, where a
unilateral injection is used, the uninjected side acts as an internal control
since there should be a lower degree of neuronal loss there. For lactacystin,
since it is an unspecific proteasomal inhibitor, potentially better negative
controls may be small molecules that would bind to the proteasome but
would either activate it or show no inhibition (Leestemaker et al., 2017).
For models of protein overexpression, such as the AAV-α-syn model,
negative controls to account for unspecific damage due to a protein being
expressed at high levels are absolutely paramount. Since, as mentioned,
expressing eGFP via AAV at the same titer as AAV-α-syn can cause similar
loss of the substantia nigra pars compacta TH+ neurons (Landeck et al.,
2016; Andersen et al., 2018). We have obtained similar results in our study
(publication II), thus demonstrating the importance of having proper
controls. Indeed, it would be necessary to have a control to compare to AAV-
α-syn that would result in α-syn-specific effects, or the model would be less
useful when considering it as a model of Parkinson’s disease, and would
rather be more similar to a toxin model. In the literature, there are instances
where injections are not compared to a control at all, or compared to an
empty vector, but a control that expresses a protein that functions similarly to
α-syn would be the most useful, so that it is clear that the effects are α-syn-
specific.
In the α-syn PFF model, the control used is often the monomeric form
of α-syn (Luk et al., 2012), in that this should not seed endogenous α-syn. We
have used PBS to control for the effect of the injection and have tested the
PFFs in KO animals, where they do not show any phosphorylated α-syn
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immunostaining (publication III). These are both good practices, however,
use of fibrils of a different pathogenic protein in wild-type mice would also be
a useful negative control. There are several options for a negative control to
use with α-syn PFFs: tau fibrils (Nonaka et al., 2010), amyloid-β fibrils
(Brahic et al., 2016), prion protein (Barron et al., 2016), SOD1 (superoxide
dismutase 1) fibrils (Chia et al., 2010), and huntingtin fibrils (Pieri et al.,
2012). Caution would need to be taken with amyloid-β fibrils since there is
the NAC region of α-syn, which could result in similarities in outcome due to
cross reactivity. However, tau fibrils would be a good candidate since
presumably the behavioural and histological outcome would be different to α-
syn PFFs (Sanders et al., 2014). Additionally, huntingtin fibrils could be
another useful control since they have been shown to be taken up and seeded
by a different mechanism than tau and α-syn fibrils (Holmes et al., 2013).
4.2 PREFORMED ALPHA-SYNUCLEIN FIBRILS
SELECTED METHODS
4.2.1 ANIMALS
2-3 month-old male mice (C57BL/6JRccHsd), approximately 1-year-
old male mice (C57Bl/6JRj), young male rats (Hsd:HanWistar and Sprague-
Dawley, starting weight approximately 250g), and approximately 1-year-old
male rats (Hsd:HanWistar) were used. All animals were under a 12-hour
light/dark cycle and had access to ad libitum food and water. Mice were
housed separately for the duration of the experiment, rats were housed in
groups of two. All surgeries and behavioural assays were carried out at the
University of Helsinki animal laboratory facilities. All animal experiments
were approved by the Finnish National Board of Animal Experiments and
were carried out according to the European Community guidelines for the use
of experimental animals. License number ESAVI/7812/04.10.07/2015.
4.2.2 PREPARATION, SONICATION, AND INJECTION OF FIBRILS
Mouse PFFs (mPFFs) were removed from -80°C, thawed, and diluted
from a 5 mg/ml stock solution using sterile PBS on the morning of the
injections. The stock solution of mPFFs were prepared at the lab of Kelvin C.
Luk (University of Pennsylvania) as previously (Volpicelli-Daley et al., 2014).
Briefly, monomeric mouse α-syn is purified from E. coli and then put into a
shaker for seven days at +37°C so that they form a fibrillar structure.
For mouse injections, a concentration of 2.5 mg/ml was used and for rat
injections 2 mg/ml. The mPFFs were then sonicated (Qsonica Microson XL
2000 Ultrasonic Liquid Processor, Newtown, CT) at power level 2 with a total
of 60 pulses, pausing briefly after every 10th pulse. Though a probe tip
sonicator was used for the experiments here, we also tested using a sonication
bath, with the protocol gained in the lab of Kelvin C. Luk. Using a Bioruptor®
water bath sonicator (Diagenode, Belgium) we first vortexed the tube
containing the diluted fibrils, then sonicated them on High mode for 10 cycles
with 30 seconds on and 30 seconds off. The tubes were gently agitated prior
to each injection and kept at room temperature throughout. We checked fibril
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size using a Dynamic Light Scattering Zetasizer (Malvern Panalytical, United
Kingdom) and electron microscope. It has been shown that fibril length and
concentration can affect the outcome of the experiment and that shorter
fibrils may be more effective at seeding inclusions and causing dopaminergic
system degeneration (Abdelmotilib et al., 2017). We observed that our
sonicated fibrils, both with a probe tip and with the sonication bath, were a
similar length as reported in the literature (Figure 4, unpublished results,
Piotr Chmielarz).
A
B
Figure 4. Electron microscopy image (A) and measured length of fibrils (B) after using a probe tip
or a bath sonicator. Size distribution is similar between both methods and in accordance with the
literature (Piotr Chmielarz, unpublished results).
Animals were anesthetized and placed into a stereotaxic frame for
intracranial injections. A 33G steel needle with a 10 μl syringe (Nanofil,
World Precision Instruments) was used to inject the fibrils in all experiments.
For mice, 2.5 µl was injected into the striatum at a 10° angle (coordinates
from bregma: A/P 0.7, M/L -2.2, D/V -3.0 from the skull), with a flow rate of
0.1 µl/minute and letting the needle rest 5 minutes after the injection
finished. For rats, 2 µl was injected into 2 sites (total volume 4 µl) of the
striatum at a 10° angle (coordinates from bregma: A/P +1.6, M/L -2.8, D/V -
6.2; A/P 0.0, M/L -4.1, D/V –6.2 from the skull), using a flow rate of 0.5
µl/minute and letting the needle rest for 5 minutes after each injection. After
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the surgery, all animals received carprofen for pain relief (Rimadyl, Pfizer, s.c.
5 mg/kg).
4.2.3 COUNTING OF PS129-POSITIVE ALPHA-SYNUCLEIN
INCLUSIONS
At the conclusion of the experiments, brains were removed and cut.
The sections were immunostained for an antibody recognizing pS129 α-syn
(rabbit anti-pS129 α-syn, Abcam, ab51523, concentration 1:10000). Number
of pS129-positive inclusions in the substantia nigra were counted manually by
an experimenter trained to recognize pS129-positive staining. 5 to 19 sections
from each brain were used from approximately A/P -4.5 to 6.0 relative to
bregma. Slides were scanned with Pannoramic 250 Flash II scanner
(3DHISTECH, Budapest, Hungary) at the service provided in the Institute of
Biotechnology, University of Helsinki. CaseViewer (3DHISTECH) software
was used to analyse the sections. The slides were scanned with single layer
20x magnification and the software allows the viewer to easily zoom in and
out of whole slide images from 0.1x up to 20x magnification, therefore the
pS129-positive staining can be identified easily by eye. Every positive
inclusion was then manually marked using the annotation function on each
section and the counts are represented as the average number of pS129
inclusions per section. Experimenter was the same for all analyses and was
blind to treatments. Brains with absolutely no visible pS129 staining present
were removed from the analysis since this indicates an unsuccessful injection
of PFFs.
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5 RESULTS
5.1 EFFECTS OF AAV-ALPHA-SYNUCLEIN INJECTED
ABOVE THE SUBSTANTIA NIGRA OF RATS (II)
We successfully recapitulated the AAV-α-syn model in rats by
unilateral injection of AAV carrying human wild-type α-syn above the
substantia nigra. This resulted in robust α-syn expression in the midbrain
and striatum (publication II, Figure 1c). Similarly to what has been published
in the literature (Decressac et al., 2012b; Febbraro et al., 2013), we were able
to repeat the striatal TH fibre loss observed, approximately 60%, and the
behavioural deficits on the cylinder test, where the rats were using the
ipsilateral paw approximately 70% of the total paw use (publication II, Figure
2a, e). However, there was large variation between animals in the degree of
loss, as well as in TH+ cells in the substantia nigra pars compacta
(publication II, Figure 2d). The striatal loss also showed no significant
correlation with amount of α-syn present (publication II, Figure 2c) or
behaviour (publication II, Figure 2f, i). We also measured dopamine content
and found that it did not correlate with the cylinder behaviour (publication II,
Figure 2h).
5.2 AAV DOWNREGULATES TH IN THE SUBSTANTIA
NIGRA PARS COMPACTA AFTER INJECTION ABOVE
THE SUBSTANTIA NIGRA (II)
We compared three distinct AAVs in a single experiment, all of which used
a 1:1 mixture of two serotypes, AAV2/2 and AAV2/5, in order to take
advantage of both of their cell entry properties (Davidson et al., 2000):
· AAV-DIO-mCherry, this vector has a double-floxed inverse open
reading frame (DIO ORF) encoding fluorescent protein mCherry. This
is a Cre-dependent vector, meaning it will not produce protein unless
Cre recombinase is present, and since the rats used here are wild-type,
no protein should be produced after transduction.
· AAV-eGFP, this vector produces fluorescent protein GFP when
injected.
· AAV-α-syn, vector carrying human wild-type α-syn.
The AAV-DIO-mCherry and AAV-eGFP were used here in order to have
two controls for AAV-α-syn – one that does not produce protein to act as a
negative control and one that does produce protein in order to control for
unspecific effects of protein overexpression. In behavioural tests, the AAV-α-
syn-injected rats performed similarly as in the above experiments and there
were no differences between the three groups (publication II, Figure 3a-b).
The same was true for the optical density measurement of TH fibres in the
striatum (publication II, Figure 3c). Though in this case the AAV-eGFP group
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showed an approximately 20% decrease and the AAV-DIO-mCherry group
showed no clear decrease in TH optical density, but there were no significant
differences between the groups. However, when dopamine content was
measured, we observed a significant drop in the AAV-eGFP group on the
injected side which we did not observe in the AAV-α-syn or AAV-DIO-
mCherry groups (publication II, Figure 3d). This resulted in a significant
difference between the AAV-α-syn and AAV-eGFP groups in dopamine
content. Interestingly, all three groups showed TH+ cell loss in the substantia
nigra pars compacta using two different counting methods (publication II,
Figure 3f-g). There were no significant differences between the groups.
Though there was a clear loss of TH+ cells, this was not accompanied by
general cell loss since there was only an approximately 20% drop in number
of Nissl+ cells in the substantia nigra pars compacta (publication II, Figure
3i). Therefore, we observed a downregulation of TH in the substantia nigra
pars compacta cells that was not accompanied by significant fibre loss in the
striatum or severe behavioural deficits.
5.3 INJECTION OF ALPHA-SYNUCLEIN PREFORMED
FIBRILS RESULTS IN WIDESPREAD PHOSPHORYLATED
ALPHA-SYNUCLEIN IN ANATOMICALLY CONNECTED
AREAS (III)
We performed experiments in both 3-month-old and one year old
wild-type mice and 1-year-old rats where α-syn mPFFs were injected to the
striatum and the brains were removed and processed 5-6 months later for
immunohistochemistry. Behaviour was performed throughout the
experiments. Experimental timeline is shown in Figure 5. For CDNF
injections, in mice CDNF was injected one month after PFF injection (Figure
5A), and in rats it was given via chronic infusion one or two months after
PFFs (Figure 5B).
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Figure 5. Experimental timelines for α-synuclein preformed fibril experiments. (A) Timeline of
experiment for mouse experiments. Preformed fibrils (PFFs) were injected to the striatum (STR)
of 3 month and 1-year-old mice at day 0 and 1 month later vehicle (PBS) or CDNF were injected
into the same location in the STR. Behavioural tests cylinder test, rotarod, and wire hanger were
performed at 1, 3, and 6 months. Animals were euthanized at 6 months and tissue was collected
for immunohistochemistry and HPLC. (B) Timeline of experiment for rat experiments. PFFs were
injected at day 0 to the STR of 1-year-old rats. Minipumps with vehicle (PBS) or CDNF at two
different doses (1.5µg/day or 3µg/day for 30 days) were installed either 1 month after PFF
injection or 2 months after PFF injection. After 1 month, the minipumps were removed. Cylinder
test was performed at baseline (before fibril injections), at 1 month (before minipump installation),
and at 4 months (2 months after minipump installation). Tissue was collected afterwards (4-5
months after fibril injection) for immunohistochemistry and HPLC. Modified from publication III.
In the case of the α-syn PFF model, we obtained prepared mouse PFFs
(mPFFs) from the laboratory of Kelvin C. Luk, where they were prepared as
previously (Volpicelli-Daley et al., 2014). We diluted, sonicated, and injected
them to the striatum of rodents. One to six months after striatal injection,
pS129 could be detected in the striatum, cortex, and substantia nigra of the
mice (Figure 6A). There was no pS129 immunostaining in mice injected with
PBS, nor in α-syn KO mice injected with mPFFs (Figure 6B-C). Therefore, we
were able to recapitulate the spreading of the PFFs in this model.
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Figure 6. Demonstration of successful fibril induction of phosphorylated α-synuclein and
spreading throughout the timepoints. (A) Wild-type mice injected with mPFFs to the striatum and
stained for α-synuclein phosphorylated at S129 (pS129) for cortex (CTX), striatum (STR), and
substantia nigra (SN) areas at 1, 3, and 6 months after mPFFs. Smaller images 2.5x
magnification and close-ups at 40x magnification. (B) Wild-type mouse injected with PBS at 6
months and immunostained with pS129 at 6 months post-injection. No visible staining present,
2.5x magnification. (C) α-synuclein knock-out (KO) mouse injected with mPFFs and
immunostained with pS129 at 1 month post-injection. No visible staining present, 10x
magnification. Modified from publication III.
5.4 EFFECTS OF ALPHA-SYNUCLEIN PREFORMED
FIBRILS AND TREATMENT WITH CDNF IN MICE AND
RATS (III)
Mice at approximately three months old and one year old were injected
with mPFFs or PBS and behaviour was performed at one, three, and six
months post-mPFF injection. At one month after mPFF injection, PBS or
CDNF were injected. At one month, adult mice injected with mPFF spend
significantly less time on rotarod than naïve mice (Figure 7A, unpaired t-test,
t=4.172 df=30, p=0.0002). In the coat hanger test, 3-month-old mice did not
show significant differences between PBS and mPFF injections (Figure 7B,
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unpaired t-test, t=1.209 df=58, p=0.2315). At 1 month, there is no clear
decrease in TH optical density (Figure 7C, average=95.55%, SEM=3.92%). At
three months after injections, 3-month-old mice also had a significant
difference on rotarod between naïve and mPFF (Figure 7D, unpaired t-test,
t=5.199 df=22, p=<0.0001). Additionally, on cylinder test performed at three
months for 3 month old mice, there was a significant difference in ipsilateral
paw use between the PBS and CDNF groups, where CDNF treated animals
were using both paws more evenly compared to PBS treated, in other words
PBS mice were using the ipsilateral paw significantly more than the
contralateral, and the CDNF mice were not (Figure 7E, two-way ANOVA,
column factor F (2, 42) = 21.51, p=<0.0001. Tukey’s multiple comparison test
as post-hoc, PBS ipsilateral vs. PBS contralateral, p=0.0051; CDNF ipsilateral
vs. CDNF contralateral, p=0.7109). There were no significant changes in
three months post-mPFF injection on TH optical density (Figure 7F, three
months, one-way ANOVA, F (2, 21) = 0.6828, p=0.5161), though this is
expected since it has been shown that the mice do not show TH loss until 6
months post-injection (Luk et al., 2012). However, at 6 months there are also
no significant differences between the groups on TH+ fibre density (Figure
7G, one-way ANOVA, F (4, 23) = 2.782, p=0.0508). Although both time
points show presence of pS129 inclusions (Figure 6).
For one-year-old mice, at one month there is no significant difference
on rotarod between PBS-injected mice and mPFF (Figure 8A, unpaired t-test,
t=0.7135 df=38, p=0.4799). Also, in the coat hanger test, one-year-old mice
did not show significant differences between PBS and mPFF injections
(Figure 8B, unpaired t-test, t=1.712 df=38, p=0.095). On wire hanger time at
three months for one-year-old mice, two months after PBS/CDNF injections,
there was a significant difference between the mice that received PFF and
then PBS or CDNF, where the CDNF-treated animals performed significantly
better than PBS-treated (Figure 8C, one-way ANOVA, F (3, 36) = 3.046,
p=0.0410, Tukey’s multiple comparison test, PFF+PBS vs. PFF+CDNF
p=0.0405).
We also modeled PFFs in one-year-old rats. PFFs were injected into
the striatum and one or two months later CDNF was given via minipump to
the striatum at two concentrations: 1.5µg/day for 30 days or 3µg/day for 30
days, with PBS as a vehicle (1xPBS/day for 30 days). The cylinder test was
used as an outcome measure. At baseline (before fibril injection) and 1 month
(before minipump installation) there were no significant differences between
treatments over time for contralateral paw use (Figure 8D, two-way ANOVA,
treatment: F (2,58)=2.788, p=0.0698; time: F (2,29)=2.448, p=0.1041;
interaction: F (4, 58)=2.048, p=0.0995). At 4 months however (2 months
after minipump installation), there was a significant difference between PBS
and CDNF 3µg/day on contralateral paw use in post hoc testing (two-way
ANOVA, Tukey’s post hoc test for multiple comparisons, p=0.0114). At four
or five months after mPFF injection, brains were removed and dopamine
concentration was measured on HPLC. For the one month minipump
experiment, there was no significant difference between the uninjected side
and injected side for the PBS (Figure 8E, two-way ANOVA, column factor, F
(2, 64) = 0.9194, p=0.4040. Tukey’s multiple comparison test as post-hoc,
PBS uninjected vs. injected side p=0.8451). There was a significant difference
between sides for the CDNF 1.5µg/day treatment (Figure 8E, two-way
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ANOVA, row factor, F (1, 64) = 10.61, p=0.0018. Tukey’s multiple comparison
test as post-hoc, CDNF 1.5µg/day uninjected vs. injected side p=0.0195), and
there was no significant difference between the sides for the CDNF 3µg/day
(Figure 8E, two-way ANOVA, column factor, F (2, 64) = 0.9194, p=0.4040.
Tukey’s multiple comparison test as post-hoc, CDNF 3µg/day uninjected vs.
injected side p=0.8315). For the counting of pS129+ inclusions four months
after mPFF injection, there were no significant differences between
treatments (Figure 8F, one-way ANOVA, F (2,31)=0.6597, p=0.5241).
Figure 7. Behaviour and pathology outcome after CDNF treatment in fibrils injected mice. (A-G)
Mouse behaviour and tyrosine hydroxylase optical density for 3-month-old mice at time of
injection. (A) Rotarod at 1 month after injection. No injection indicates naïve mice, PFF only
denotes fibrils were given at day 0. (B) Wire hanger time at 1 month after injection. PBS only and
PFF only indicate that the injections were given on day 0. (C) Tyrosine hydroxylase optical density
in the striatum as a percent of the control side at 1 month after PFF injection. (D) Rotarod at 3
months after injection. No injection indicates naïve mice, PFF only denotes fibrils were given at
day 0. (E) Cylinder test at 3 months after injection, graph represents ipsilateral, contralateral, as
well as both paw touches on the cylinder wall. PFF+PBS/PFF+CDNF indicates that PFFs were
given at day 0 and PBS/CDNF was given 1 month later. (F) Tyrosine hydroxylase optical density
in the striatum as a percent of the control side 3 months after fibrils. PFF only indicates PFFs
given at day 0, and PFF+PBS/CDNF fibrils given at day 0 and PBS/CDNF 1 month later. (G)
Tyrosine hydroxylase optical density in the striatum as a percent of the control side. PBS/PFF
only indicates PBS or PFFs given at day 0 and no other injections, PBS+PBS indicates PBS given
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at day 0 and again 1 month later, PFF+PBS/CDNF indicates fibrils at day 0 and PBS/CDNF 1
month later. Bars represent mean ± SEM. Figure modified from publication III.
Figure 8. Behaviour and pathology outcome after CDNF treatment in fibrils injected mice and
rats, rodents one year old at time of injection. (A-C) Mouse behaviour for 1-year-old mice at time
of injection. (A) Rotarod 1 month after injection. PBS/PFF only indicates PBS for fibrils given at
day 0. (B) Wire hanger time 1 month after injection. PBS/PFF only indicates PBS or fibrils given at
day 0. (C) Wire hanger time 3 months after injection. PBS/PFF only indicates PBS or PFFs given
at day 0 and no other injections, PBS+PBS indicates PBS given at day 0 and again 1 month later,
PFF+PBS/CDNF indicates fibrils at day 0 and PBS/CDNF 1 month later. (D-F) Behaviour and
pathological outcome for 1-year-old rats at time of injection. (D) Contralateral paw use for rats
(percent of total paw use). Baseline indicates before fibrils were injected, 1 month is 1 month after
fibrils but before installation of minipumps, and 4 months is 4 months after fibrils and 3 months
after treatment. Minipumps administer treatment to the striatum for 30 days. (E) Dopamine
concentration in the striatum as a percentage of the control side at 4 months after fibril injection.
(F) Number of pS129 inclusions in the substantia nigra for each treatment 4 months after fibril
injections. Data is presented as the average number of inclusions per section counted. Bars
represent mean ± SEM. Figure modified from publication III.
5.5 EFFECTS OF A SINGLE INJECTION OF CDNF TO
THE SUBSTANTIA NIGRA OR IN COMBINATION TO THE
STRIATUM IN THE 6-OHDA MODEL IN RATS
There were no significant weight changes after injections of human
CDNF and 6-OHDA to rats throughout the experiment (Figure 9A). The
amphetamine-induced rotations over the time-course of the experiment are
shown in Figure 9B. At 8 weeks post-lesion, both CDNF treatments showed a
significant decrease in amphetamine-induced rotations compared to vehicle
(Two-way ANOVA, treatment effect, F (2, 50)= 6.207, p=0.0039, time effect,
F (2, 100) = 4.929, p=0.0091, treatment X time interaction, F (4, 100) = 1.85,
p=0.1251; post-hoc Tukey’s multiple comparison test, CDNF 3µg SN
p=0.007, CDNF combination STR+SN p=0.0003) (Figure 9B). However, 12
weeks post-lesion, only the combination of striatal and nigral CDNF
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treatment showed a significant difference compared to vehicle (Two-way
ANOVA, treatment effect of, F (2, 50)=6.207, p=0.0039; post-hoc Tukey’s
multiple comparison test, CDNF 3µg SN p=0.1102, CDNF combination
p=0.0254)  (Figure 9B). Total ipsilateral paw use at each measured time point
is presented in Figure 9C. At 4 weeks post-lesion, rats injected with 3 μg of
CDNF to the substantia used the ipsilateral paw significantly less than vehicle
treated rats (One-way ANOVA, F (2, 40) = 4.065, p= 0.0461, Dunnett’s
multiple comparison as post-hoc test). There were no significant differences
in ipsilateral paw use between either of the CDNF treated groups at 8 weeks
(One-way ANOVA F (2, 41) = 0.2777, p= 0.7590) or 12 weeks (One-way
ANOVA, F (2, 39) = 0.3026, p= 0.7406) post-lesion compared to vehicle.
Figure 9. Amphetamine-induced rotations and cylinder test after 6-OHDA and CDNF
administration. (A) Weight of animals throughout the entire experiment. No significant differences
at any of the time points between treatment groups were observed. (B) Time course of rotations
from 2 to 12 weeks. 6-OHDA was given at week 0 and 2 weeks later the CDNF treatments were
administered. At 8 weeks after 6-OHDA, there was a significant effect of both treatments (Two-
way ANOVA, post-hoc Tukey’s multiple comparison test,*CDNF STR 10µg+SN 3µg, p=0.0254;
**CDNF SN 3µg, p=0.007; ***CDNF STR 10µg+SN 3µg, p=0.0003). Vehicle n= 22; CDNF SN 3µg
n=16; CDNF STR 10µg+SN 3µg n=15. (C) Time course of cylinder test from 4 to 12 weeks
representing the total ipsilateral paw use (ipsilateral touches / ipsilateral + contralateral + both
touches). There was a significant difference for rats treated with 3µg of CDNF to SN at 4 weeks
(One-way ANOVA, post-hoc Dunnett’s multiple comparison, *CDNF SN 3µg, p= 0.0461). Vehicle
n= 19; CDNF 10µg STR n=15; CDNF SN 3µg n=13; CDNF STR 10µg+SN 3µg n=11. Bars
represent mean ± SEM. Figure from unpublished results.
A severe lesion model was used here (Back et al., 2013a; Penttinen et
al., 2016), where CDNF as a single injection has not been tested before.
Consequently, no significant differences were seen between vehicle and
CDNF treatments in the optical density of TH immunoreactive fibres in the
striatum at 12 weeks post-lesion (One-way ANOVA, F (2, 50) = 1.039, p=
0.3613) (Figure 10B) or in the number of TH+ cells in the substantia nigra
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pars compacta (One-way ANOVA, F (2, 49) = 1.42, p= 0.2515) (Figure 9D) 12
weeks after the lesion. Additionally, DAT immunoreactive striatal fibres were
analysed (Figure 10E), however, no significant differences between vehicle
and CDNF treatments were observed at 12 weeks post-lesion (One-way
ANOVA, F (2, 32) = 0.9134, p=0.4114) (Figure 10F).
Figure 10. Dopamine system outcome measures. Amount in µg indicates amount of CDNF
protein. (A) Representative striatal slices with TH immunohistochemistry for each treatment group,
magnification 1x. (B) TH optical density of the striatum represented as a percent of the control
(non-injected) side. (C) Representative nigral slices with TH immunohistochemistry for each
treatment group, magnification 1,5x. (D) The number of TH-positive cells in the substantia nigra
as a percent of the control (non-injected) side. (E) Representative striatal slices of DAT
immunohistochemistry for each treatment, magnification 1x. (F) DAT optical density of striatum as
a percent of the control (non-injected) side. Values are represented as a percent of the non-
injected side as they are not absolute cell counts. Bars represent mean ± SEM, statistical analysis
using one-way ANOVA. Figure from unpublished results.
5.6 DIFFUSION AND LOCALIZATION OF CDNF AFTER
INJECTION TO THE RAT SUBSTANTIA NIGRA (IV)
To quantitatively study the diffusion and transport of intrastriatally
injected CDNF to other brain areas, and to repeat the previously published
data (Voutilainen et al., 2011), as well as have a positive control, 125I-labelled
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CDNF was injected to the striatum of rats, and 24 hours later dissected brain
areas were measured in a gamma counter (Figure 11A-B). CDNF spread
intensely to the frontal cortex of the injected side, while there was little
spread of 125I-CDNF to other cortical areas. CDNF also spread well to the
ipsilateral and contralateral hippocampus, and substantia nigra (Figure 11A-
B). Next, we wanted to analyze CDNF diffusion after nigral administration
and possible anterograde transport from substantia nigra to striatum which
has not been studied previously. CDNF labelled with 125I was injected into the
substantia nigra of rats and brain areas dissected 24 hours later were
measured in a gamma counter (Figure 11C-D). CDNF diffused most strongly
to the ipsilateral STN from the substantia nigra. The radioactivity in the
ipsilateral substantia nigra was the highest overall, with it being significantly
different than the other brain areas (excluding the STN) (One-way ANOVA, F
(11, 52) = 8.6, p= <0.0001) (Figure 11C). To study whether the spread of
CDNF to the STN was due to passive diffusion or active transport, 125I-CDNF
was injected to the substantia nigra together with two doses of unlabelled
CDNF (2000-fold molar excess or 10000-fold molar excess) to compete for
binding and anterograde axonal transport of the labelled CDNF. The
diffusion/transport of 125I-CDNF from the substantia nigra to the STN was
not blocked by either of the doses of unlabelled CDNF (One-way ANOVA, F
(2, 18) = 0.0068, low: p=0.9801, df=52; high: p=0.9928, df=52) (Figure 11E)
which suggests passive diffusion of CDNF after nigral administration.
Figure 11. Diffusion of 125I-CDNF when injected to the striatum or substantia nigra of naïve
rats. A-B) Percentage of the total radioactivity (calculated based on radioactivity of all brain areas
measured) after injecting radiolabeled CDNF into the STR of naive rats and measuring 24 h later,
ipsilateral regions (A) and contralateral (B). C-D) Percentage of the total radioactivity (calculated
based on radioactivity of all brain areas measured) after injecting radiolabeled CDNF into the SN
of naive rats and measuring 24 h later, ipsilateral regions (C) and contralateral (D). E-F) 2000x or
10 000x molar excess of cold (unlabeled) CDNF was given together with radiolabeled CDNF to
SN of naïve rats and measured 24h later. Ipsilateral regions (E) and contralateral (F). (n=5-6/brain
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region) Bars represent mean ± SEM. ****p=<0.0001. FCTX= frontal cortex, CTX= cortex, STR=
striatum, HC= hippocampus, SN= substantia nigra, GP= globus pallidus, STN= subthalamic
nucleus. Figure modified from publication IV.
When CDNF protein was injected to the substantia nigra of the naïve
rat brain and monitored at different time points in order to characterize the
diffusion after nigral injection, we observed robust CDNF staining in the
ipsilateral midbrain, including the substantia nigra, at the 2 (Figure 12A) and
6 (Figure 12B) hour time points, but not at the 24 hour time point (Figure
12C). Additionally, CDNF protein appeared to diffuse anteriorly and
posteriorly from the substantia nigra at 2 and 6 hours, but again was not
detected at 24 hours. At the 2- and 6-hour time points, there was clear
staining in the hippocampus and amygdala, as well as thalamic and
hypothalamic regions. There was no staining observed in the dorsal striatum
at any of the time points. Additionally, increasing the volume of the CDNF
injection while keeping the total amount of protein constant, increased its
diffusion in the substantia nigra. When 1 or 4 µl of CDNF was injected to the
substantia nigra of naïve rats, the higher volume appeared to diffuse farther
after 2 hours as compared to the lower volume (Figure 12D). It can also be
observed that at higher magnifications there are concentrated, darkly stained,
puncta throughout the injected area (Figure 12E, black arrow heads).
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Figure 12. Diffusion of human CDNF after injection to the substantia nigra in naïve rat brain.
CDNF (3µg in 4µl) was injected to the SN of rats and perfused (A) 2, (B) 6, or (C) 24 hours later.
Human CDNF (hCDNF) immunostaining of a representative posterior, nigral, thalamic, and striatal
section for each time point. N=2/time point. (D) Diffusion of human CDNF (3µg) when injected into
the SN in the volume of 1µl or 4µl. Rats were perfused 2 hours after the injection. Images shown
at increasing magnification of the CDNF injected side versus the uninjected side. (E) 40x
magnification of injected area. Black arrowheads indicate dark brown puncta staining of CDNF.
Figure modified from publication IV.
Next, we wanted to determine whether CDNF colocalized with TH+
neurons or parvalbumin (PV) neurons using immunofluorescent staining and
confocal microscopy. Brains from six rats were analyzed to clarify whether
CDNF colocalized with either of the neuronal subtypes. Out of several cells
detected in the nigral area of each brain, it can be observed that there are
CDNF immunoreactive puncta (cyan, white arrows) inside the TH+ neurons
(magenta, Figure 13A) on the injected side. By contrast, from the PV stained
sections, CDNF is diffused around the neurons but does not appear to
colocalize with them as clearly as in the TH (Figure 13B). Additionally, as can
be observed in Figure 12, there is diffuse CDNF staining all around the
midbrain, including the substantia nigra. The confocal images show the same:
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CDNF is diffused around the cells and only some cells hold CDNF-
immunoreactive puncta as demonstrated in Figure 12.
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Figure 13. Representative confocal images of CDNF-injected rat substantia nigra with TH
neurons or PV neurons to demonstrate colocalization. (A) Representative confocal images from a
rat brain injected with human CDNF into the substantia nigra and perfused 2 hours later with
costaining for CDNF and TH. Total of 6 rats were injected and stained for the colocalization study.
White arrows in the injected side indicate CDNF immunoreactive puncta (cyan dots). Uninjected
side representative image taken with identical settings to account for possible background. Top
panel 10x objective, lower panel 63x objective. (B) Representative confocal images from rats
injected with human CDNF into the substantia nigra and perfused 2 hrs later with costaining for
CDNF and PV (parvalbumin). Uninjected side representative image taken with identical settings to
account for possible background. Top panels 10x objective, lower panels 63x objective, N=6.
Figure modified from publication IV.
5.7 BEHAVIOUR AND HISTOLOGICAL OUTCOMES OF
LACTACYSTIN-INJECTED MICE (V)
In addition to the three models used above, we used a lactacystin
model to induce dopamine neuron degeneration and buildup of α-syn. We
were able to recapitulate the model in approximately 2-month-old and 1-year-
old mice by injecting lactacystin to the right substantia nigra (publication V).
Specifically, the mice showed increased use of the ipsilateral paw on the
cylinder test (publication V, Figure 1a-b). They also had a unilateral loss of
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TH in the striatum and substantia nigra, as well as decreased dopamine and
DOPAC (3,4-dihydroxyphenylacetic acid) content in the striatum (publication
V, Figure 2). The mice also showed increased neuroinflammatory markers
GFAP (glial fibrillary acidic protein) and Iba1 (ionized calcium binding
adaptor molecule 1), markers for astrocytes and microglia, respectively, that
were spread throughout the ipsilateral side (publication V, Figure 3), and
increased α-syn immunoreactivity in the injected substantia nigra
(publication V, Figure 5). However, whether these forms were insoluble could
not be verified in this study.
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6 DISCUSSION
We set out to utilize and validate α-syn-based Parkinson’s disease
models to test CDNF and other therapies. Additionally, we performed studies
to complement previous CDNF characterization studies. While we were able
to repeat what has been published for these models, we have also outlined
some drawbacks to them; and in regard to CDNF therapy, we have shown
some positive effects in both toxin and α-syn-based models.
6.1 AAV-ALPHA-SYNUCLEIN MODEL (II)
The AAV-α-syn model has been extensively utilized in rodents (see
Table 3) to unilaterally overexpress human wild-type α-syn in the
nigrostriatal tract and incur TH loss as well as typical behavioural deficits
used in Parkinson’s disease toxin models such as cylinder test and rotational
assays. It has been touted as a more physiologically relevant model for
Parkinson’s disease research than toxin models since there is α-syn present.
In our studies, we were able to repeat across several experiments the TH loss
and behavioural deficits on the cylinder test that have been published
previously (publication II). However, the high variation between animals and
lack of correlation between outcome measures would make it a difficult model
to test therapies on. Since the degree of TH loss in the AAV-α-syn-injected
animals did not correlate with behaviour on the cylinder test or amount of α-
syn present, from these alone it would be impossible to determine which
animals had a successful lesion. Therefore, other behaviour tests would need
to be tested to determine if they had a higher correlation with TH loss. Or
then a method to test in live animals whether there is a deficit in the
dopamine system would be useful, such as SPECT/CT technology which
combines single-photon emission computed tomography and computed
tomography, and radioligands for DAT (Back et al., 2013b). Although this
would not solve the issues we encountered when overexpressing control
AAVs.
Toxicity to cells with overexpression of high levels of AAV-eGFP has
been reported previously (Klein et al., 2006), as well as a robust immune
response (Samaranch et al., 2014). In the latter study, AAV9-eGFP from
jellyfish injected into non-human primates resulted in cell death and an
increase in reactive astrocytes and microglia at the transduced area in the
striatum. Also, the two animals that received AAV9-eGFP to the cisterna
magna had decreased appetite, ataxia, and impaired balance and hand-eye
coordination, which was most likely a result of deficits in cell function in the
Purkinje cells in the cerebellum as well as astrocyte and microglia activation
there. By contrast, the non-human primates that received AAV9-AADC from
human showed no such issues and appeared similarly to the control animal in
behaviour and histology. This is unsurprisingly since GFP is a non-
mammalian protein, and though it is widely used as a control in biological
studies, its incompatibility with non-human primates and rodents is clear.
Related to this, AAV-eGFP is often used as a control in AAV-α-syn studies,
and it has been shown that if it is expressed at similar levels to AAV-α-syn it
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will cause loss of TH+ substantia nigra pars compacta cells (Koprich et al.,
2011; Landeck et al., 2016). In fact, we observed this in publication II, where
AAV5-eGFP caused a higher degree of TH loss in the striatum and resulted in
a high number of amphetamine-induced rotations compared to AAV5-α-syn.
When we explored this further, we found that when we compared AAV2/2
and AAV2/5 mixtures of AAV-α-syn, AAV-eGFP, and AAV-DIO-mCherry,
where the latter should not express protein in wild-type animals since they
lack Cre recombinase, that all three vectors downregulated TH in the
substantia nigra pars compacta neurons on the injected side. While this result
was clear from visual examination of the sections, we quantified it using two
validated methods for counting of TH+ cells in the substantia nigra pars
compacta (Penttinen et al., 2016; Penttinen et al., 2018a). We also quantified
the Nissl+ cells in the substantia nigra pars compacta and found only a small
decrease, indicating that this seems to be a loss of the TH phenotype rather
than a global loss of cells. This loss of phenotype has been observed with long
term overexpression of GDNF via AAV (Georgievska et al., 2002; Penttinen et
al., 2018b). We can hypothesize how it may be occurring here, one possibility
is that since TH is a highly regulated enzyme in dopamine synthesis it is easily
downregulated when AAV is applied. If this is the case, a different marker of
dopamine would be needed here to more accurately measure the degree of
loss, such as VMAT2 which has been used rarely in AAV-α-syn studies as a
secondary marker to TH (Decressac et al., 2011). However, in its current form
the AAV-α-syn model is not an ideal model for an α-syn-based Parkinson’s
disease animal model where issues with between animal variation, controls,
and its dissimilarity to the human disease, need to be considered. Since α-syn
is expressed here at very high, non-physiological levels, we can conclude that
it is causing downregulation and dysfunction to a degree that would not be
observed in disease. While it is of course common to use models that show
faster disease onset for practical purposes, there is likely a more useful model
than AAV overexpression that would not cause toxicity to cells due to high
protein levels. However, if one would want to use this model, a better control
is needed. We have recommended proteins that are derived from mammals
that would form oligomers that are not prone to misfolding, such as
cytoskeletal proteins actin or collagen.
6.2  PREFORMED ALPHA-SYNUCLEIN FIBRILS MODEL
AND CDNF (III)
The PFF model of α-syn-based Parkinson’s disease in rodents has been
characterized only relatively recently as of this writing, but it is increasingly
being used by researchers. When the PFFs are injected into the animal it has
a slower onset than toxin or AAV models, results in dopamine loss and motor
deficits, and it often shows α-syn spreading from its injection location. Here,
we were able to reliably show the spread of pS129 α-syn in the mouse and rat
brain, as well as some motor deficits (publication III). However, loss of TH
was relatively absent in mice (publication III). This was in contrast to (Luk et
al., 2012), where there was a decrease in TH in the striatum and a loss of
dopamine neurons in the substantia nigra six months after mPFF injection in
mice. There are a couple of possible explanations for this discrepancy since
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we do observe that the PFFs are acting as shown previously in the literature.
One is that the mouse strain used is more resistant to TH loss by increased α-
syn load, possibly due to lower levels of endogenous α-syn or then some other
unknown mechanism. In the abovementioned paper the authors used the
strain C57BL6/C3H F1 (Luk et al., 2012), which is a mix between C57BL/6J
females and C3H/HeJ males. According to The Jackson Laboratory where the
mice were obtained, this strain may “create or enhance expression of
polygenic diseases”, however there is currently no further information about
α-syn expression in this strain (The Jackson Laboratory, 2018). Another
explanation is that a longer time point was needed to observe changes.
Further studies would be needed to confirm either of these explanations.
Since in the model we do have some motor behaviour changes, we
tested CDNF as a possible therapy. In the instances where we do see a deficit,
in this case in cylinder test in mice and rats and the coat hanger test in mice,
CDNF was able to restore the behaviour. We have some hints for how this
may be occurring from our in vitro data (publication III). First, we observed
an interaction between α-syn and CDNF in vitro using a microscale
thermophoresis assay, indicating that CDNF may be acting directly on α-syn
to exert effects. Data from primary mouse cortical neurons showed that
CDNF decreased the level of pS129 α-syn and in primary mouse hippocampal
culture CDNF reduced the internalization of the fibrils. However, in neurons
treated with PFFs, CDNF increased the number of cells that were positive for
pS129; there was no effect observed in vivo. Although in these neuronal
culture experiments there was no cell loss, we cannot rule out a functional
deficit. However, our conflicting results with the fibrils may be indicative that
this is not a physiological situation since in the cell-based experiments we
administered the PFFs via viral overexpression or transient transfection and
this likely does not represent expected levels. Although in this case, we
observe effects with CDNF and the PFF model which could be related to a
direct interaction with α-syn. As mentioned, there have been fewer studies
with CDNF, but we can use MANF as a proxy for what may be occurring with
CDNF since they share 59% amino acid identity (Lindholm et al., 2007). Both
proteins have an ER retention signal at the C-terminus, and with MANF it has
been shown that expression increases with activators of the UPR (Apostolou
et al., 2008). Aggregation of α-syn has been shown to correlate with
activation of the UPR in relation to the ER in human and animal models of
Parkinson’s disease (Hoozemans et al., 2007; Bellucci et al., 2011b), and it
may be that CDNF is acting in this manner, either directly or indirectly
(Arancibia et al., 2018). For MANF, there are published studies indicating
that this could be occurring. MANF is able to protect cells from ER stress in a
calcium-dependent manner, possibly via direct interaction with the ER
chaperone GRP78 (glucose-regulated protein 78) (Glembotski et al., 2012),
and related to this, GRP78 has been shown to bind to the mutant prion
protein at the ER, and consequently mediate its degradation at the
proteasome (Jin et al., 2000). If we consider that α-syn may be acting in a
similar way to the prion protein, as has been described previously (Brundin &
Melki, 2017), it is possible that MANF, acting as a cofactor to GRP78, would
have a similar effect in our model. Additionally, MANF has been shown to be
upregulated in a model utilizing mutated matrilin-3, a protein that is
aggregated in models of multiple epiphyseal dysplasia (Hartley et al., 2013).
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Though the disease is not related to Parkinson’s disease, mutated matrilin-3
causes ER stress and activation of the UPR (Nundlall et al., 2010). In the
aforementioned study, MANF was shown to form a complex with matrilin-3
that included GRP78. Based on GRP78 and/or MANF’s involvement with
prion and aggregating proteins, it is possible that CDNF may act in the same
way with α-syn. Further studies are certainly needed to ascertain which
effects CDNF may be having in relation to α-syn.
6.3 EFFECTS OF CDNF INJECTED TO THE
SUBSTANTIA NIGRA IN 6-OHDA AND NAÏVE RATS (IV)
We used the toxin 6-OHDA to lesion the dopamine neurons of the
striatum of rats and tested CDNF injections to the substantia nigra alone or in
combination to the substantia nigra and the striatum. While we observed
some functional recovery on behaviour with CDNF, it was unable to restore
the TH+ fibres, TH+ neurons, or DAT fibres in the brain (unpublished data).
At 12 weeks, when the immunohistochemistry measurements were
performed, only the combination of striatal and nigral CDNF restored the
behaviour on amphetamine-induced rotations, not the nigral injection alone.
Likely, CDNF given to substantia nigra was not a robust enough treatment to
restore behaviour at this time, especially since striatal administration of
CDNF has been successful in the rat 6-OHDA model (Lindholm et al., 2007;
Voutilainen et al., 2011). Since at 12 weeks there was no restoration of TH or
DAT with either CDNF treatment, we can conclude that it was not working
here. To compare to the first study (Lindholm et al., 2007), possible reasons
for the discrepancy are that a single injection of 6-OHDA was used, rather
than administered between two sites, and CDNF was administered four weeks
after the lesion instead of two, as we have used here. For the second study
mentioned above where CDNF was successful in the striatum (Voutilainen et
al., 2011), a chronic infusion paradigm was used where CDNF was
continuously administered to the striatum of rats over a two-week period, not
as a single injection as we have done in this case. Additionally, the 6-OHDA
injection paradigm we used here can cause increased variation, and we have
since switched to a more stable lesion paradigm where 3μg or 6μg is
distributed between 3 sites, since the 20μg of 6-OHDA distributed equally to
two sites has been shown to be less stable (Penttinen et al., 2016). Examining
the data more closely indicates that some of the control rats may not have a
severe lesion, in other words their striatal TH optical density is between
approximately 50% and 75%, and therefore we cannot rule out that the effects
observed for CDNF here are due to a smaller lesion, rather than a therapeutic
effect. It is possible that for these reasons there was no significant restoration
of dopamine neurons in this study with CDNF.
We also characterized nigral injection of CDNF to naïve rats
(publication IV). Striatal administration of CDNF was thoroughly
characterized previously (Matlik et al., 2017), where it was transported
retrogradely to the substantia nigra after injection. Inside the striatum it was
shown to be present both extracellularly and in the cytoplasm, and
interestingly, it was detected inside substantia nigra TH+ neurons of naïve
rats. Radiolabelled CDNF has also been shown to be transported retrogradely
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after striatal injection to non-lesioned rats within 24 hours (Voutilainen et al.,
2011). We were able to repeat the latter result where radiolabelled CDNF
spread to the cortex, both sides of the striatum, and the hippocampus after
injection to the striatum after 24 hours. For our study, CDNF was injected to
the substantia nigra and it remained in the ipsilateral side and only diffused
as far as the STN. CDNF did not seem to be transported or diffused to the
striatum here, which is in line with the immunohistochemistry data. When
unlabelled protein was used to block the transport of radiolabelled CDNF
after nigral injection, neither the 2000- nor the 10000-molar excess of
unlabelled protein could block the diffusion of CDNF to the STN. Therefore,
we can conclude that CDNF is not undergoing active anterograde transport to
the striatum, but rather passive diffusion after nigral administration.
Interestingly, only radiolabelled CDNF was present in the brain regions 24
hours after the injection. The discrepancy between the radioactivity
measurements and the immunohistochemistry results could be due to the
limit of detection for the antibody used. Although there was no anterograde
transport of CDNF from substantia nigra to striatum, we did observe similar
diffusion of CDNF around the midbrain. This occurred at 2 and 6 hours, but
not 24 hours, possibly due to CDNF’s half-life of 5.5 hours (Matlik et al.,
2017), and that it could have already diffused significantly and therefore was
not detectable by immunohistochemistry at the lower concentrations present
at 24 hours. Also, since CDNF diffused farther when it was diluted to a higher
volume, this could increase the areas where CDNF is able to exert its effects,
as has been observed with GDNF (Taylor et al., 2013). Here, we also
measured qualitatively whether CDNF was being taken up to TH+ or PV+
neurons of the substantia nigra after injection, since it has been shown with
TH in the striatum as mentioned above. Using confocal microscopy, we
observed CDNF inside TH+ neurons as well as around them in the substantia
nigra area six hours after injection. However, we found that fewer PV+
neurons had CDNF puncta, and it was diffused around the cells. PV was
chosen as another neuronal type since they are important in Parkinson’s
(Bernacer et al., 2012). From these results, it is possible to conclude that
CDNF may be acting intracellularly in TH+ neurons and extracellularly at
both TH+ and PV+ neurons, though we cannot conclude that it is acting at all
here, since we have not elucidated a cellular mechanism of how CDNF may
affect dopamine neuron survival or function. In general, though CDNF did
not have a positive effect in the 6-OHDA model in this particular case, we
were able to characterize the effects of CDNF at the substantia nigra in order
to complement ongoing preclinical and clinical studies.
6.4 COMPARISON OF PARKINSON’S DISEASE ANIMAL
MODELS
Clearly, there is a large variety of Parkinson’s animal models to choose
from: toxin, genetic, viral overexpression, preformed fibrils, or a
combination. One is not necessarily better than the other, nor is there a
perfect animal model to recapitulate the human disease. In this thesis, we
used four models: 6-OHDA, lactacystin, AAV, and PFF. Each of these have
advantages and disadvantages, and a researcher may choose one based on
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their own specific needs. Table 6 lists the main advantages and disadvantages
of some popular Parkinson’s disease models.
Table 6. This table summarizes the main advantages and disadvantages to popularly used animal
models in how they best recapitulate sporadic Parkinson’s disease in humans.
Model Advantage Disadvantage
6-OHDA or MPTP Fast onset, selectively
destroys dopamine neurons
No α-synuclein present
Lactacystin α-synuclein present,
dopamine neuron
degeneration, and
behavioural deficits
Protein buildup is not α-
synuclein-specific
Genetic Familial forms can be studied Inconsistent dopamine
degeneration, lack of α-
synuclein present, highly
dependent on mouse strain
Adeno-associated viral
vector
α-synuclein present,
dopamine neuron
degeneration, and
behavioural deficits
Does not recapitulate
sporadic human disease,
problems with unspecific
protein overexpression
Preformed fibrils Model of progressive Lewy
pathology spreading, slow
onset
Inconsistent outcomes in
behaviour and dopamine
neuron loss
There is currently no single model that would perfectly encapsulate the
dopamine neuron degeneration, loss or dysfunction in other neuronal
systems such as cholinergic, motor and non-motor symptoms, and the
presence of progressive α-syn aggregation that is observed in sporadic human
Parkinson’s disease. Though several come close, and we cannot discount the
work that has already been done in order to find a suitable model to test
therapies on and discover the cause of the disease. However, continuous work
is likely needed to further characterize and test new and existing models for
Parkinson’s disease, whether they are animal, cell, or some form of patient-
derived samples.
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7 CONCLUSIONS
The aim of this thesis was to use α-syn to model Parkinson’s disease in
rodents to test CDNF and other potential therapies on. The main conclusions
from the studies are as follows:
1. Overexpression of human wild-type α-syn via AAV to model
Parkinson’s disease in rats results in TH downregulation and mild
behavioural deficits similar to the literature, however there is high
variation between animals and typical outcome measures do not
correlate. Importantly, control AAVs also result in downregulation of
TH and make it difficult to conclude that the effects in this model are
specific to α-syn.
2. When α-syn PFFs are injected into the striatum of rodents, there is
spread of pS129 α-syn to anatomically connected areas such as cortex
and substantia nigra pars compacta. There are mild behavioural effects
that can be ameliorated by CDNF, however there is no loss of TH in the
striatum.
3. Injection of CDNF to the substantia nigra of naïve rats results in its
widespread diffusion in the midbrain, including the STN, and CDNF is
taken up by TH+ cells of the substantia nigra. However, there is no
evidence of anterograde transport of CDNF from the substantia nigra
to the striatum.
4. Lactacystin, a proteasomal inhibitor, administered to the substantia
nigra of mice results in unilateral increase of α-syn, degeneration of
the nigrostriatal dopamine system, behavioural deficits, and increase
in neuroinflammatory markers, thus repeating what has been
published for this model.
In general, the α-syn rodent Parkinson’s models were modelled here
relatively successfully, with the caveat that caution needs to be taken when
setting up these models and proper positive and negative controls are needed.
Additionally, CDNF was tested to complement ongoing clinical trials in
Parkinson’s disease.
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